{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:17:26Z","timestamp":1788344246785,"version":"build-2803163510"},"reference-count":308,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rucker Family Fellowship Award"},{"name":"Jastro-Shields Research Award"},{"name":"Mar Family Fellowship"},{"DOI":"10.13039\/100017995","name":"Nora Eccles Treadwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Litov Research and Mentoring Excellence seed award"},{"name":"UC Davis Environmental Health Sciences Center","award":["P30 ES023513"],"award-info":[{"award-number":["P30 ES023513"]}]},{"name":"National Institutes of Health, United States","award":["R01AG085572"],"award-info":[{"award-number":["R01AG085572"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Approximately one-third of people with diabetes have diabetic kidney disease (DKD), and DKD remains a leading cause of kidney failure in the United States. DKD is characterized by injury to the glomerular filtration barrier and renal tubulointerstitium, arising from complex and convergent metabolic, hemodynamic, and inflammatory insults. Tyrosine phosphorylation, a reversible post-translational modification, is a central regulatory mechanism in these pathways and is dynamically controlled by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). Aberrant tyrosine phosphorylation is a hallmark of DKD and implicates PTPs as key modulators of podocyte, endothelial, tubular, and immune cell dysfunction. Over 100 genes code for PTPs in humans, with 38 \u2018classical\u2019 PTPs that specifically target tyrosine motifs, including receptor-type and non-receptor-type subtypes. Several classical PTPs are implicated in DKD pathogenesis, while others are increasingly associated with signaling cascades that drive renal metabolism, inflammation, fibrosis, and cell death. There is growing interest in PTPs as their contributions to the disease emerge, though the role(s) of some remain uncharacterized in DKD. Moreover, recent breakthroughs in pharmaceuticals targeting PTPs for metabolic diseases and cancer have ignited interest in repurposing or tailoring PTP\u2011directed therapeutics for DKD. This review summarizes current knowledge and recent advances of classical PTPs in DKD, including their roles in insulin signaling, cellular architecture, and glomerular and tubular cell injury. It further discusses existing DKD treatments and highlights emerging strategies to pharmacologically modulate PTP activity, such as active\u2011site inhibitors, allosteric agents, and antibody\u2011targeting approaches. By integrating mechanistic insights with drug discovery efforts, this review outlines how targeting specific PTPs could complement current standard\u2011of\u2011care therapies and open new avenues for precision treatment of DKD.<\/jats:p>","DOI":"10.1186\/s12929-026-01282-7","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:50:02Z","timestamp":1788342602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of classical protein tyrosine phosphatases in diabetic kidney disease and therapeutic implications"],"prefix":"10.1186","volume":"33","author":[{"given":"Grace","family":"LeBleu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz G.","family":"Haj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1282_CR1","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.2337\/dc26-S011","volume":"49","author":"Chronic Kidney Disease and Risk Management","year":"2025","unstructured":"Chronic Kidney Disease and Risk Management. Standards of care in diabetes\u20142026. Diabetes Care. 2025;49:S246\u201360. https:\/\/doi.org\/10.2337\/dc26-S011.","journal-title":"Diabetes Care"},{"key":"1282_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70098","volume":"17","author":"Y He","year":"2025","unstructured":"He Y, Wang X, Li L, Liu M, Wu Y, Chen R, et al. Global, regional, and national prevalence of chronic type 2 diabetic kidney disease from 1990 to 2021: a trend and health inequality analyses based on the global burden of disease study 2021. J Diabetes. 2025;17:e70098. https:\/\/doi.org\/10.1111\/1753-0407.70098.","journal-title":"J Diabetes"},{"key":"1282_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100873","volume":"6","author":"K Kim","year":"2024","unstructured":"Kim K, Crook J, Lu C-C, Nyman H, Sarker J, Nelson R, et al. Healthcare costs across diabetic kidney disease stages: a veterans affairs study. Kidney Med. 2024;6:100873. https:\/\/doi.org\/10.1016\/j.xkme.2024.100873.","journal-title":"Kidney Med"},{"key":"1282_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.689083","author":"K Ebefors","year":"2021","unstructured":"Ebefors K, Lass\u00e9n E, Anandakrishnan N, Azeloglu EU, Daehn IS. Modeling the glomerular filtration barrier and intercellular crosstalk. Front Physiol. 2021. https:\/\/doi.org\/10.3389\/fphys.2021.689083.","journal-title":"Front Physiol"},{"key":"1282_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41581-024-00907-0","volume":"21","author":"AB Fogo","year":"2025","unstructured":"Fogo AB, Harris RC. Crosstalk between glomeruli and tubules. Nat Rev Nephrol. 2025;21:189\u201399. https:\/\/doi.org\/10.1038\/s41581-024-00907-0.","journal-title":"Nat Rev Nephrol"},{"key":"1282_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/CS20210625","volume":"136","author":"F Barutta","year":"2022","unstructured":"Barutta F, Bellini S, Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy. Clin Sci. 2022;136:493\u2013520. https:\/\/doi.org\/10.1042\/CS20210625.","journal-title":"Clin Sci"},{"key":"1282_CR7","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1681\/ASN.2005010055","volume":"16","author":"BL Wharram","year":"2005","unstructured":"Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin\u2013induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16:2941. https:\/\/doi.org\/10.1681\/ASN.2005010055.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR8","doi-asserted-by":"publisher","first-page":"18485","DOI":"10.1038\/s41598-019-54692-z","volume":"9","author":"A Minakawa","year":"2019","unstructured":"Minakawa A, Fukuda A, Sato Y, Kikuchi M, Kitamura K, Wiggins RC, et al. Podocyte hypertrophic stress and detachment precedes hyperglycemia or albuminuria in a rat model of obesity and type2 diabetes-associated nephropathy. Sci Rep. 2019;9:18485. https:\/\/doi.org\/10.1038\/s41598-019-54692-z.","journal-title":"Sci Rep."},{"key":"1282_CR9","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/ki.2012.234","volume":"82","author":"EJ Weil","year":"2012","unstructured":"Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int. 2012;82:1010\u20137. https:\/\/doi.org\/10.1038\/ki.2012.234.","journal-title":"Kidney Int"},{"key":"1282_CR10","doi-asserted-by":"publisher","first-page":"e20431","DOI":"10.1371\/journal.pone.0020431","volume":"6","author":"M Zheng","year":"2011","unstructured":"Zheng M, Lv L-L, Ni J, Ni H-F, Li Q, Ma K-L, et al. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy. PLoS ONE. 2011;6:e20431. https:\/\/doi.org\/10.1371\/journal.pone.0020431.","journal-title":"PLoS ONE"},{"key":"1282_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1681\/ASN.2021030294","volume":"33","author":"NC Finch","year":"2022","unstructured":"Finch NC, Fawaz SS, Neal CR, Butler MJ, Lee VK, Salmon AJ, et al. Reduced glomerular filtration in diabetes is attributable to loss of density and increased resistance of glomerular endothelial cell fenestrations. J Am Soc Nephrol. 2022;33:1120\u201336. https:\/\/doi.org\/10.1681\/ASN.2021030294.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2337\/db23-0455","volume":"73","author":"S Fawaz","year":"2024","unstructured":"Fawaz S, Martin Alonso A, Qiu Y, Ramnath R, Stowell-Connolly H, Gamez M, et al. Adiponectin reduces glomerular endothelial glycocalyx disruption and restores glomerular barrier function in a mouse model of type 2 diabetes. Diabetes. 2024;73:964\u201376. https:\/\/doi.org\/10.2337\/db23-0455.","journal-title":"Diabetes"},{"key":"1282_CR13","first-page":"318","volume":"162","author":"CK Abrass","year":"1995","unstructured":"Abrass CK. Diabetic nephropathy. Mechanisms of mesangial matrix expansion. West J Med. 1995;162:318\u201321.","journal-title":"West J Med."},{"key":"1282_CR14","doi-asserted-by":"publisher","first-page":"R1009","DOI":"10.1152\/ajpregu.00809.2010","volume":"300","author":"V Vallon","year":"2011","unstructured":"Vallon V. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1009\u201322. https:\/\/doi.org\/10.1152\/ajpregu.00809.2010.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1282_CR15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1242\/dmm.019398","volume":"8","author":"H-F Jheng","year":"2015","unstructured":"Jheng H-F, Tsai P-J, Chuang Y-L, Shen Y-T, Tai T-A, Chen W-C, et al. Albumin stimulates renal tubular inflammation through an HSP70-TLR4 axis in mice with early diabetic nephropathy. Dis Model Mech. 2015;8:1311\u201321. https:\/\/doi.org\/10.1242\/dmm.019398.","journal-title":"Dis Model Mech"},{"key":"1282_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/hmg\/ddad166","volume":"33","author":"L Wei","year":"2024","unstructured":"Wei L, Gao J, Wang L, Tao Q, Tu C. Multi-omics analysis reveals the potential pathogenesis and therapeutic targets of diabetic kidney disease. Hum Mol Genet. 2024;33:122\u201337. https:\/\/doi.org\/10.1093\/hmg\/ddad166.","journal-title":"Hum Mol Genet"},{"key":"1282_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00693","author":"AC Lay","year":"2018","unstructured":"Lay AC, Coward RJM. The evolving importance of insulin signaling in podocyte health and disease. Front Endocrinol. 2018. https:\/\/doi.org\/10.3389\/fendo.2018.00693.","journal-title":"Front Endocrinol"},{"key":"1282_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cmet.2010.08.015","volume":"12","author":"GI Welsh","year":"2010","unstructured":"Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 2010;12:329\u201340. https:\/\/doi.org\/10.1016\/j.cmet.2010.08.015.","journal-title":"Cell Metab"},{"key":"1282_CR19","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2337\/db06-0693","volume":"56","author":"RJM Coward","year":"2007","unstructured":"Coward RJM, Welsh GI, Koziell A, Hussain S, Lennon R, Ni L, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes. 2007;56:1127\u201335. https:\/\/doi.org\/10.2337\/db06-0693.","journal-title":"Diabetes"},{"key":"1282_CR20","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1038\/s41388-019-0705-x","volume":"38","author":"C-Y Yang","year":"2019","unstructured":"Yang C-Y, Chang P-W, Hsu W-H, Chang H-C, Chen C-L, Lai C-C, et al. Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration. Oncogene. 2019;38:4075\u201394. https:\/\/doi.org\/10.1038\/s41388-019-0705-x.","journal-title":"Oncogene"},{"key":"1282_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119590","volume":"1871","author":"M-F Hsu","year":"2024","unstructured":"Hsu M-F, Ito Y, Singh JP, Hsu S-F, Wells A, Jen K-Y, et al. Protein tyrosine phosphatase 1B is a regulator of alpha-actinin4 in the glomerular podocyte. Biochim Biophys Acta Mol Cell Res. 2024;1871:119590. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119590.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1282_CR22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1998.275.5.C1216","author":"MB Marrero","year":"1998","unstructured":"Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol Cell Physiol. 1998. https:\/\/doi.org\/10.1152\/ajpcell.1998.275.5.C1216.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1282_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.cellsig.2006.08.010","volume":"19","author":"MD Godeny","year":"2007","unstructured":"Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, et al. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cell Signal. 2007;19:600\u20139. https:\/\/doi.org\/10.1016\/j.cellsig.2006.08.010.","journal-title":"Cell Signal"},{"key":"1282_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01394-9","volume":"21","author":"C Yu","year":"2023","unstructured":"Yu C, Li Z, Nie C, Chang L, Jiang T. Targeting Src homology phosphatase 2 ameliorates mouse diabetic nephropathy by attenuating ERK\/NF-\u03baB pathway-mediated renal inflammation. Cell Commun Signal. 2023;21:362. https:\/\/doi.org\/10.1186\/s12964-023-01394-9.","journal-title":"Cell Commun Signal"},{"key":"1282_CR25","doi-asserted-by":"publisher","first-page":"8379327","DOI":"10.1155\/2017\/8379327","volume":"2017","author":"S Fakhruddin","year":"2017","unstructured":"Fakhruddin S, Alanazi W, Jackson KE. Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. J Diabetes Res. 2017;2017:8379327. https:\/\/doi.org\/10.1155\/2017\/8379327.","journal-title":"J Diabetes Res"},{"key":"1282_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-025-00882-9","author":"T Tiganis","year":"2025","unstructured":"Tiganis T, Tonks NK. Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases. Nat Rev Mol Cell Biol. 2025. https:\/\/doi.org\/10.1038\/s41580-025-00882-9.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"11","key":"1282_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrm2039","volume":"7","author":"NK Tonks","year":"2006","unstructured":"Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833\u201346. https:\/\/doi.org\/10.1038\/nrm2039.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"1282_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/febs.13600","volume":"283","author":"A Alonso","year":"2016","unstructured":"Alonso A, Pulido R. The extended human PTPome: a growing tyrosine phosphatase family. FEBS J. 2016;283:1404\u201329. https:\/\/doi.org\/10.1111\/febs.13600.","journal-title":"FEBS J"},{"key":"1282_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.5483\/BMBRep.2012.45.12.240","volume":"45","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Ryu SE. Structure and catalytic mechanism of human protein tyrosine phosphatome. BMB Rep. 2012;45:693\u20139. https:\/\/doi.org\/10.5483\/BMBRep.2012.45.12.240.","journal-title":"BMB Rep"},{"key":"1282_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.70128","volume":"241","author":"G LeBleu","year":"2026","unstructured":"LeBleu G, Hsu M, Ito Y, Liang S, Ma K, Meng T, et al. Mapping of PTP1B, TCPTP, SHP2, and putative substrates reveals novel networks in glomerular podocytes. J Cell Physiol. 2026;241:e70128. https:\/\/doi.org\/10.1002\/jcp.70128.","journal-title":"J Cell Physiol"},{"key":"1282_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MNH.0000000000000376","volume":"27","author":"P Geraldes","year":"2018","unstructured":"Geraldes P. Protein phosphatases and podocyte function. Curr Opin Nephrol Hypertens. 2018;27:49. https:\/\/doi.org\/10.1097\/MNH.0000000000000376.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1282_CR32","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1016\/s0021-9258(18)83508-6","volume":"264","author":"RA Mooney","year":"1989","unstructured":"Mooney RA, Anderson DL. Phosphorylation of the insulin receptor in permeabilized adipocytes is coupled to a rapid dephosphorylation reaction. J Biol Chem. 1989;264:6850\u20137. https:\/\/doi.org\/10.1016\/s0021-9258(18)83508-6.","journal-title":"J Biol Chem"},{"key":"1282_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/mcb.10.2.458","volume":"10","author":"NK Tonks","year":"1990","unstructured":"Tonks NK, Cicirelli MF, Diltz CD, Krebs EG, Fischer EH. Effect of microinjection of a low-Mr human placenta protein tyrosine phosphatase on induction of meiotic cell division in Xenopus oocytes. Mol Cell Biol. 1990;10:458\u201363. https:\/\/doi.org\/10.1128\/mcb.10.2.458.","journal-title":"Mol Cell Biol"},{"key":"1282_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1042\/bj2840569","volume":"284","author":"N Hashimoto","year":"1992","unstructured":"Hashimoto N, Zhang WR, Goldstein BJ. Insulin receptor and epidermal growth factor receptor dephosphorylation by three major rat liver protein-tyrosine phosphatases expressed in a recombinant bacterial system. Biochem J. 1992;284:569\u201376. https:\/\/doi.org\/10.1042\/bj2840569.","journal-title":"Biochem J"},{"key":"1282_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1210\/mend.10.5.8732688","volume":"10","author":"WR Zhang","year":"1996","unstructured":"Zhang WR, Li PM, Oswald MA, Goldstein BJ. Modulation of insulin signal transduction by eutopic overexpression of the receptor-type protein-tyrosine phosphatase LAR. Mol Endocrinol. 1996;10:575\u201384. https:\/\/doi.org\/10.1210\/mend.10.5.8732688.","journal-title":"Mol Endocrinol"},{"key":"1282_CR36","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1172\/JCI115131","volume":"87","author":"J Meyerovitch","year":"1991","unstructured":"Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest. 1991;87:1286\u201394. https:\/\/doi.org\/10.1172\/JCI115131.","journal-title":"J Clin Invest"},{"key":"1282_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117774","author":"UO Wenzel","year":"1995","unstructured":"Wenzel UO, Fouqueray B, Biswas P, Grandaliano G, Choudhury GG, Abboud HE. Activation of mesangial cells by the phosphatase inhibitor vanadate. Potential implications for diabetic nephropathy. J Clin Investig. 1995. https:\/\/doi.org\/10.1172\/JCI117774.","journal-title":"J Clin Investig"},{"key":"1282_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcdb.2014.09.020","volume":"37","author":"J Bakke","year":"2015","unstructured":"Bakke J, Haj FG. Protein-tyrosine phosphatase 1B substrates and metabolic regulation. Semin Cell Dev Biol. 2015;37:58\u201365. https:\/\/doi.org\/10.1016\/j.semcdb.2014.09.020.","journal-title":"Semin Cell Dev Biol"},{"key":"1282_CR39","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1128\/MCB.20.15.5479-5489.2000","volume":"20","author":"LD Klaman","year":"2000","unstructured":"Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol. 2000;20:5479\u201389. https:\/\/doi.org\/10.1128\/MCB.20.15.5479-5489.2000.","journal-title":"Mol Cell Biol"},{"key":"1282_CR40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/10409238.2013.819830","volume":"48","author":"M Feldhammer","year":"2013","unstructured":"Feldhammer M, Uetani N, Miranda-Saavedra D, Tremblay ML. PTP1B: a simple enzyme for a complex world. Crit Rev Biochem Mol Biol. 2013;48:430\u201345. https:\/\/doi.org\/10.3109\/10409238.2013.819830.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"1282_CR41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1126\/science.283.5407.1544","volume":"283","author":"M Elchebly","year":"1999","unstructured":"Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1544\u20138. https:\/\/doi.org\/10.1126\/science.283.5407.1544.","journal-title":"Science"},{"key":"1282_CR42","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.2337\/diab.45.10.1379","volume":"45","author":"BL Seely","year":"1996","unstructured":"Seely BL, Staubs PA, Reichart DR, Berhanu P, Milarski KL, Saltiel AR, et al. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes. 1996;45:1379\u201385. https:\/\/doi.org\/10.2337\/diab.45.10.1379.","journal-title":"Diabetes"},{"key":"1282_CR43","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.ajpath.2014.05.005","volume":"184","author":"T Kumagai","year":"2014","unstructured":"Kumagai T, Baldwin C, Aoudjit L, Nezvitsky L, Robins R, Jiang R, et al. Protein tyrosine phosphatase 1B inhibition protects against podocyte injury and proteinuria. Am J Pathol. 2014;184:2211\u201324. https:\/\/doi.org\/10.1016\/j.ajpath.2014.05.005.","journal-title":"Am J Pathol"},{"key":"1282_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.metabol.2017.07.009","volume":"76","author":"Y Ito","year":"2017","unstructured":"Ito Y, Hsu M-F, Bettaieb A, Koike S, Mello A, Calvo-Rubio M, et al. Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury. Metabolism. 2017;76:56\u201369. https:\/\/doi.org\/10.1016\/j.metabol.2017.07.009.","journal-title":"Metabolism"},{"key":"1282_CR45","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms24076532","volume":"24","author":"SM Al-Qabbaa","year":"2023","unstructured":"Al-Qabbaa SM, Qaboli SI, Alshammari TK, Alamin MA, Alrajeh HM, Almuthnabi LA, et al. Sitagliptin mitigates diabetic nephropathy in a rat model of streptozotocin-induced type 2 diabetes: possible role of PTP1B\/JAK-STAT pathway. Int J Mol Sci. 2023;24:6532. https:\/\/doi.org\/10.3390\/ijms24076532.","journal-title":"Int J Mol Sci"},{"key":"1282_CR46","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78207","volume":"17","author":"D Katagiri","year":"2025","unstructured":"Katagiri D, Nagasaka S, Takahashi K, Shimizu A, Harris RC, Takahashi T. Protein tyrosine phosphatase 1B (PTP1B) deficiency substantially attenuates glomerular injury in endothelial nitric oxide synthase (eNOS)-deficient diabetic mice. Cureus. 2025;17:e78207. https:\/\/doi.org\/10.7759\/cureus.78207.","journal-title":"Cureus"},{"key":"1282_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41419-021-03629-4","volume":"12","author":"T Huang","year":"2021","unstructured":"Huang T, Li X, Wang F, Lu L, Hou W, Zhu M, et al. The CREB\/KMT5A complex regulates PTP1B to modulate high glucose-induced endothelial inflammatory factor levels in diabetic nephropathy. Cell Death Dis. 2021;12:333. https:\/\/doi.org\/10.1038\/s41419-021-03629-4.","journal-title":"Cell Death Dis."},{"key":"1282_CR48","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1038\/s41598-018-22233-9","volume":"8","author":"KL Garner","year":"2018","unstructured":"Garner KL, Betin VMS, Pinto V, Graham M, Abgueguen E, Barnes M, et al. Enhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress. Sci Rep. 2018;8:3902. https:\/\/doi.org\/10.1038\/s41598-018-22233-9.","journal-title":"Sci Rep."},{"key":"1282_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep12987","author":"X Zhang","year":"2015","unstructured":"Zhang X, Han X, Tang Y, Wu Y, Qu B, Shen N. miR-744 enhances type I interferon signaling pathway by targeting PTP1B in primary human renal mesangial cells. Sci Rep. 2015. https:\/\/doi.org\/10.1038\/srep12987.","journal-title":"Sci Rep"},{"key":"1282_CR50","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1084\/jem.20180009","volume":"216","author":"IA Carota","year":"2019","unstructured":"Carota IA, Kenig-Kozlovsky Y, Onay T, Scott R, Thomson BR, Souma T, et al. Targeting VE-PTP phosphatase protects the kidney from diabetic injury. J Exp Med. 2019;216:936\u201349. https:\/\/doi.org\/10.1084\/jem.20180009.","journal-title":"J Exp Med"},{"key":"1282_CR51","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1172\/JCI7236","volume":"106","author":"BL Wharram","year":"2000","unstructured":"Wharram BL, Goyal M, Gillespie PJ, Wiggins JE, Kershaw DB, Holzman LB, et al. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J Clin Invest. 2000;106:1281\u201390. https:\/\/doi.org\/10.1172\/JCI7236.","journal-title":"J Clin Invest"},{"key":"1282_CR52","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1681\/ASN.0000000640","volume":"36","author":"J Weinmann-Menke","year":"2025","unstructured":"Weinmann-Menke J, Gonzalez-Sanchez HM, Iwata Y, Meineck M, Abassi N, Marini F, et al. Ptprz signaling, tubule-mediated and macrophage-mediated kidney injury, and subsequent CKD. J Am Soc Nephrol. 2025;36:1295. https:\/\/doi.org\/10.1681\/ASN.0000000640.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.kint.2023.06.038","volume":"104","author":"F Lizotte","year":"2023","unstructured":"Lizotte F, Rousseau M, Denhez B, L\u00e9vesque D, Guay A, Liu H, et al. Deletion of protein tyrosine phosphatase SHP-1 restores SUMOylation of podocin and reverses the progression of diabetic kidney disease. Kidney Int. 2023;104:787\u2013802. https:\/\/doi.org\/10.1016\/j.kint.2023.06.038.","journal-title":"Kidney Int"},{"key":"1282_CR54","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41598-017-00564-3","volume":"7","author":"M-F Hsu","year":"2017","unstructured":"Hsu M-F, Bettaieb A, Ito Y, Graham J, Havel PJ, Haj FG. Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria. Sci Rep. 2017;7:461. https:\/\/doi.org\/10.1038\/s41598-017-00564-3.","journal-title":"Sci Rep"},{"key":"1282_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04517-6","volume":"79","author":"M-F Hsu","year":"2022","unstructured":"Hsu M-F, Ito Y, Afkarian M, Haj FG. Deficiency of the Src homology phosphatase 2 in podocytes is associated with renoprotective effects in mice under hyperglycemia. Cell Mol Life Sci. 2022;79:516. https:\/\/doi.org\/10.1007\/s00018-022-04517-6.","journal-title":"Cell Mol Life Sci"},{"key":"1282_CR56","doi-asserted-by":"publisher","first-page":"780","DOI":"10.2337\/db23-0700","volume":"73","author":"X Han","year":"2024","unstructured":"Han X, Wei J, Zheng R, Tu Y, Wang M, Chen L, et al. Macrophage SHP2 deficiency alleviates diabetic nephropathy via suppression of MAPK\/NF-\u03baB\u2013 dependent inflammation. Diabetes. 2024;73:780\u201396. https:\/\/doi.org\/10.2337\/db23-0700.","journal-title":"Diabetes"},{"key":"1282_CR57","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbrc.2020.12.030","volume":"550","author":"Y Lin","year":"2021","unstructured":"Lin Y, Shao Z, Zhao M, Li J, Xu X. PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy. Biochem Biophys Res Commun. 2021;550:62\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2020.12.030.","journal-title":"Biochem Biophys Res Commun"},{"key":"1282_CR58","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/MCB.00956-15","volume":"36","author":"R Verma","year":"2016","unstructured":"Verma R, Venkatareddy M, Kalinowski A, Patel SR, Salant DJ, Garg P. Shp2 associates with and enhances nephrin tyrosine phosphorylation and is necessary for foot process spreading in mouse models of podocyte injury. Mol Cell Biol. 2016;36:596\u2013614. https:\/\/doi.org\/10.1128\/MCB.00956-15.","journal-title":"Mol Cell Biol"},{"key":"1282_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1042\/BST20253102","volume":"54","author":"CL Pierotti","year":"2026","unstructured":"Pierotti CL, K\u00f6hn M. Regulation and activity of the phosphatase SHP2: SH2 domains, dephosphorylation activity, and beyond. Biochem Soc Trans. 2026;54:15\u201324. https:\/\/doi.org\/10.1042\/BST20253102.","journal-title":"Biochem Soc Trans"},{"key":"1282_CR60","doi-asserted-by":"publisher","first-page":"E1188","DOI":"10.1152\/ajpendo.00560.2012","volume":"304","author":"N Drapeau","year":"2013","unstructured":"Drapeau N, Lizotte F, Denhez B, Guay A, Kennedy CR, Geraldes P. Expression of SHP-1 induced by hyperglycemia prevents insulin actions in podocytes. Am J Physiol Endocrinol Metab. 2013;304:E1188\u201398. https:\/\/doi.org\/10.1152\/ajpendo.00560.2012.","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"1282_CR61","doi-asserted-by":"publisher","first-page":"27455","DOI":"10.1074\/jbc.M100556200","volume":"276","author":"BD Cuevas","year":"2001","unstructured":"Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem. 2001;276:27455\u201361. https:\/\/doi.org\/10.1074\/jbc.M100556200.","journal-title":"J Biol Chem"},{"key":"1282_CR62","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1074\/jbc.M114.612721","volume":"290","author":"B Denhez","year":"2015","unstructured":"Denhez B, Lizotte F, Guimond M-O, Jones N, Takano T, Geraldes P. Increased SHP-1 protein expression by high glucose levels reduces nephrin phosphorylation in podocytes*. J Biol Chem. 2015;290:350\u20138. https:\/\/doi.org\/10.1074\/jbc.M114.612721.","journal-title":"J Biol Chem"},{"key":"1282_CR63","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nm.2052","volume":"15","author":"P Geraldes","year":"2009","unstructured":"Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, et al. Activation of PKC-\u03b4 and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15:1298\u2013306. https:\/\/doi.org\/10.1038\/nm.2052.","journal-title":"Nat Med"},{"key":"1282_CR64","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.34067\/KID.0002152022","volume":"3","author":"F Lizotte","year":"2022","unstructured":"Lizotte F, Robillard S, Lavoie N, Rousseau M, Denhez B, Moreau J, et al. Enhanced SHP-1 expression in podocyturia is associated with kidney dysfunction in patients with diabetes. Kidney360. 2022;3:1710. https:\/\/doi.org\/10.34067\/KID.0002152022.","journal-title":"Kidney360"},{"key":"1282_CR65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/35067005","volume":"2","author":"N Jones","year":"2001","unstructured":"Jones N, Iljin K, Dumont DJ, Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol. 2001;2:257\u201367. https:\/\/doi.org\/10.1038\/35067005.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1282_CR66","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1038\/sj.onc.1202992","volume":"18","author":"G Fachinger","year":"1999","unstructured":"Fachinger G, Deutsch U, Risau W. Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the Angiopoietin receptor Tie-2. Oncogene. 1999;18:5948\u201353. https:\/\/doi.org\/10.1038\/sj.onc.1202992.","journal-title":"Oncogene"},{"key":"1282_CR67","doi-asserted-by":"publisher","first-page":"e70058","DOI":"10.14814\/phy2.70058","volume":"12","author":"R Rana","year":"2024","unstructured":"Rana R, Natoli TA, Khandelwal P, Pissios P, Muhammad AB, Chipashvili V, et al. VEPTP inhibition with an extracellular domain targeting antibody did not restore albuminuria in a mouse model of diabetic kidney disease. Physiol Rep. 2024;12:e70058. https:\/\/doi.org\/10.14814\/phy2.70058.","journal-title":"Physiol Rep"},{"key":"1282_CR68","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1681\/ASN.0000000000000098","volume":"34","author":"Y Li","year":"2023","unstructured":"Li Y, Liu P, Zhou Y, Maekawa H, Silva JB, Ansari MJ, et al. Activation of angiopoietin-Tie2 signaling protects the kidney from ischemic injury by modulation of endothelial-specific pathways. J Am Soc Nephrol. 2023;34:969\u201387. https:\/\/doi.org\/10.1681\/ASN.0000000000000098.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR69","doi-asserted-by":"publisher","first-page":"19953","DOI":"10.1016\/S0021-9258(17)32113-0","volume":"269","author":"PE Thomas","year":"1994","unstructured":"Thomas PE, Wharram BL, Goyal M, Wiggins JE, Holzman LB, Wiggins RC. GLEPP1, a renal glomerular epithelial cell (podocyte) membrane protein-tyrosine phosphatase. Identification, molecular cloning, and characterization in rabbit. J Biol Chem. 1994;269:19953\u201361. https:\/\/doi.org\/10.1016\/S0021-9258(17)32113-0.","journal-title":"J Biol Chem"},{"key":"1282_CR70","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1159\/000054736","volume":"90","author":"YH Kim","year":"2002","unstructured":"Kim YH, Goyal M, Wharram B, Wiggins J, Kershaw D, Wiggins R. GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis: a marker of acute podocyte injury. Nephron. 2002;90:471\u20136. https:\/\/doi.org\/10.1159\/000054736.","journal-title":"Nephron"},{"key":"1282_CR71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.ki.5002302","volume":"72","author":"LC Clement","year":"2007","unstructured":"Clement LC, Liu G, Perez-Torres I, Kanwar YS, Avila-Casado C, Chugh SS. Early changes in gene expression that influence the course of primary glomerular disease. Kidney Int. 2007;72:337\u201347. https:\/\/doi.org\/10.1038\/sj.ki.5002302.","journal-title":"Kidney Int"},{"key":"1282_CR72","doi-asserted-by":"publisher","first-page":"721202","DOI":"10.3389\/fendo.2021.721202","volume":"12","author":"Z Gao","year":"2021","unstructured":"Gao Z, Li X, Li X, Sui L. Identification of key candidate genes and chemical perturbagens in diabetic kidney disease using integrated bioinformatics analysis. Front Endocrinol. 2021;12:721202. https:\/\/doi.org\/10.3389\/fendo.2021.721202.","journal-title":"Front Endocrinol"},{"key":"1282_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.34067\/KID.0000000620","volume":"6","author":"HH Ward","year":"2024","unstructured":"Ward HH, Anquetil F, Das V, Gibson CB, Dovmark TH, Kusmartseva I, et al. Network for pancreatic organ donors with diabetes-kidney. Kidney360. 2024;6:15\u201326. https:\/\/doi.org\/10.34067\/KID.0000000620.","journal-title":"Kidney360"},{"key":"1282_CR74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/147323000703500308","volume":"35","author":"J Tian","year":"2007","unstructured":"Tian J, Ping Wang H, Ying Mao Y, Jin J, Hua Chen J. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin a nephropathy. J Int Med Res. 2007;35:338\u201345. https:\/\/doi.org\/10.1177\/147323000703500308.","journal-title":"J Int Med Res"},{"key":"1282_CR75","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.cub.2009.09.048","volume":"19","author":"G Tarcic","year":"2009","unstructured":"Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, et al. An unbiased screen identifies the DEP-1 tumour suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol. 2009;19:1788\u201398. https:\/\/doi.org\/10.1016\/j.cub.2009.09.048.","journal-title":"Curr Biol"},{"key":"1282_CR76","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1128\/MCB.01374-08","volume":"29","author":"C Chabot","year":"2009","unstructured":"Chabot C, Spring K, Gratton J-P, Elchebly M, Royal I. New role for the protein tyrosine phosphatase DEP-1 in akt activation and endothelial cell survival. Mol Cell Biol. 2009;29:241\u201353. https:\/\/doi.org\/10.1128\/MCB.01374-08.","journal-title":"Mol Cell Biol"},{"key":"1282_CR77","doi-asserted-by":"publisher","first-page":"16219","DOI":"10.1074\/jbc.275.21.16219","volume":"275","author":"M Kovalenko","year":"2000","unstructured":"Kovalenko M, Denner K, Sandstr\u00f6m J, Persson C, Gro\u03b2 S, Jandt E, et al. Site-selective dephosphorylation of the platelet-derived growth factor \u03b2-receptor by the receptor-like protein-tyrosine phosphatase DEP-1*. J Biol Chem. 2000;275:16219\u201326. https:\/\/doi.org\/10.1074\/jbc.275.21.16219.","journal-title":"J Biol Chem"},{"key":"1282_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309754","volume":"11","author":"M Bai","year":"2024","unstructured":"Bai M, Xu S, Jiang M, Guo Y, Hu D, He J, et al. Meis1 targets protein tyrosine phosphatase receptor J in fibroblast to retard chronic kidney disease progression. Adv Sci. 2024;11:2309754. https:\/\/doi.org\/10.1002\/advs.202309754.","journal-title":"Adv Sci"},{"key":"1282_CR79","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1440-1797.2011.01451.x","volume":"16","author":"A Advani","year":"2011","unstructured":"Advani A, Wiggins KJ, Cox AJ, Zhang Y, Gilbert RE, Kelly DJ. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology. 2011;16:573\u201381. https:\/\/doi.org\/10.1111\/j.1440-1797.2011.01451.x.","journal-title":"Nephrology"},{"key":"1282_CR80","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1681\/ASN.2014020192","volume":"26","author":"J Chen","year":"2015","unstructured":"Chen J, Chen J-K, Harris RC. EGF receptor deletion in podocytes attenuates diabetic nephropathy. J Am Soc Nephrol. 2015;26:1115\u201325. https:\/\/doi.org\/10.1681\/ASN.2014020192.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR81","doi-asserted-by":"publisher","first-page":"F647","DOI":"10.1152\/ajprenal.00288.2019","volume":"318","author":"K Takahashi","year":"2020","unstructured":"Takahashi K, Kim RH, Pasic L, He L, Nagasaka S, Katagiri D, et al. Agonistic anti-CD148 monoclonal antibody attenuates diabetic nephropathy in mice. Am J Physiol Ren Physiol. 2020;318:F647\u201359. https:\/\/doi.org\/10.1152\/ajprenal.00288.2019.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1282_CR82","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/dmrr.415","volume":"19","author":"RB Caldwell","year":"2003","unstructured":"Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19:442\u201355. https:\/\/doi.org\/10.1002\/dmrr.415.","journal-title":"Diabetes Metab Res Rev"},{"key":"1282_CR83","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nature03987","volume":"437","author":"SM Weis","year":"2005","unstructured":"Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature. 2005;437:497\u2013504. https:\/\/doi.org\/10.1038\/nature03987.","journal-title":"Nature"},{"key":"1282_CR84","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1046\/j.1523-1755.2000.07717.x","volume":"58","author":"DR Cha","year":"2000","unstructured":"Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int. 2000;58:S104\u201312. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.07717.x.","journal-title":"Kidney Int"},{"key":"1282_CR85","doi-asserted-by":"publisher","first-page":"e61916","DOI":"10.1371\/journal.pone.0061916","volume":"8","author":"C Michaloglou","year":"2013","unstructured":"Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS ONE. 2013;8:e61916. https:\/\/doi.org\/10.1371\/journal.pone.0061916.","journal-title":"PLoS ONE"},{"key":"1282_CR86","doi-asserted-by":"publisher","first-page":"7669","DOI":"10.1074\/jbc.RA119.011801","volume":"295","author":"P Fu","year":"2020","unstructured":"Fu P, Ramchandran R, Shaaya M, Huang L, Ebenezer DL, Jiang Y, et al. Phospholipase D2 restores endothelial barrier function by promoting PTPN14-mediated VE-cadherin dephosphorylation. J Biol Chem. 2020;295:7669\u201385. https:\/\/doi.org\/10.1074\/jbc.RA119.011801.","journal-title":"J Biol Chem"},{"key":"1282_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03014-7","author":"B Fu","year":"2020","unstructured":"Fu B, Yin S, Lin X, Shi L, Wang Y, Zhang S, et al. PTPN14 aggravates inflammation through promoting proteasomal degradation of SOCS7 in acute liver failure. Cell Death Dis. 2020. https:\/\/doi.org\/10.1038\/s41419-020-03014-7.","journal-title":"Cell Death Dis."},{"key":"1282_CR88","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1128\/MCB.23.6.2096-2108.2003","volume":"23","author":"S Galic","year":"2003","unstructured":"Galic S, Klingler-Hoffmann M, Fodero-Tavoletti MT, Puryer MA, Meng T-C, Tonks NK, et al. Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP. Mol Cell Biol. 2003;23:2096\u2013108. https:\/\/doi.org\/10.1128\/MCB.23.6.2096-2108.2003.","journal-title":"Mol Cell Biol"},{"key":"1282_CR89","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1128\/MCB.25.2.819-829.2005","volume":"25","author":"S Galic","year":"2005","unstructured":"Galic S, Hauser C, Kahn BB, Haj FG, Neel BG, Tonks NK, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol. 2005;25:819\u201329. https:\/\/doi.org\/10.1128\/MCB.25.2.819-829.2005.","journal-title":"Mol Cell Biol"},{"key":"1282_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1742-4658.2012.08563.x","volume":"280","author":"T Tiganis","year":"2013","unstructured":"Tiganis T. PTP1B and TCPTP \u2013 nonredundant phosphatases in insulin signaling and glucose homeostasis. FEBS J. 2013;280:445\u201358. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08563.x.","journal-title":"FEBS J"},{"key":"1282_CR91","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1111\/jcmm.14304","volume":"23","author":"Y Li","year":"2019","unstructured":"Li Y, Zhou H, Li Y, Han L, Song M, Chen F, et al. PTPN2 improved renal injury and fibrosis by suppressing STAT\u2010induced inflammation in early diabetic nephropathy. J Cell Mol Med. 2019;23:4179\u201395. https:\/\/doi.org\/10.1111\/jcmm.14304.","journal-title":"J Cell Mol Med"},{"key":"1282_CR92","doi-asserted-by":"publisher","first-page":"3984797","DOI":"10.1155\/2018\/3984797","volume":"2018","author":"L Zheng","year":"2018","unstructured":"Zheng L, Zhang W, Li A, Liu Y, Yi B, Nakhoul F, et al. PTPN2 downregulation is associated with albuminuria and vitamin D receptor deficiency in type 2 diabetes mellitus. J Diabetes Res. 2018;2018:3984797. https:\/\/doi.org\/10.1155\/2018\/3984797.","journal-title":"J Diabetes Res"},{"key":"1282_CR93","doi-asserted-by":"publisher","first-page":"16499","DOI":"10.1038\/s41598-021-94984-x","volume":"11","author":"LJ Newbury","year":"2021","unstructured":"Newbury LJ, Simpson K, Khalid U, John I, de Rivera LB, Lu Y-A, et al. miR-141 mediates recovery from acute kidney injury. Sci Rep. 2021;11:16499. https:\/\/doi.org\/10.1038\/s41598-021-94984-x.","journal-title":"Sci Rep"},{"key":"1282_CR94","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1681\/asn.2015040439","volume":"27","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Skelton LA, Xu L, Chandler MP, Berthiaume JM, Boron WF. Role of receptor protein tyrosine phosphatase \u03b3 in sensing extracellular CO2 and HCO3. J Am Soc Nephrol. 2016;27:2616\u201321. https:\/\/doi.org\/10.1681\/asn.2015040439.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.108834","author":"R Peng","year":"2024","unstructured":"Peng R, Zuo S, Li X, Huang Y, Chen S, Zou X, et al. Investigating HMGB1 as a potential serum biomarker for early diabetic nephropathy monitoring by quantitative proteomics. iScience. 2024. https:\/\/doi.org\/10.1016\/j.isci.2024.108834.","journal-title":"iScience"},{"key":"1282_CR96","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/icb.1997.68","volume":"75","author":"JG Altin","year":"1997","unstructured":"Altin JG, Sloan EK. The role of CD45 and CD45-associated molecules in T cell activation. Immunol Cell Biol. 1997;75:430\u201345. https:\/\/doi.org\/10.1038\/icb.1997.68.","journal-title":"Immunol Cell Biol"},{"key":"1282_CR97","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/ndt\/gfw260","volume":"32","author":"CQF Klessens","year":"2017","unstructured":"Klessens CQF, Zandbergen M, Wolterbeek R, Bruijn JA, Rabelink TJ, Bajema IM, et al. Macrophages in diabetic nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant. 2017;32:1322\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfw260.","journal-title":"Nephrol Dial Transplant"},{"key":"1282_CR98","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1523-1755.2004.00367.x","volume":"65","author":"F Chow","year":"2004","unstructured":"Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116\u201328. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00367.x.","journal-title":"Kidney Int"},{"key":"1282_CR99","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejphar.2017.12.016","volume":"820","author":"W Lv","year":"2018","unstructured":"Lv W, Booz GW, Wang Y, Fan F, Roman RJ. Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets. Eur J Pharmacol. 2018;820:65\u201376. https:\/\/doi.org\/10.1016\/j.ejphar.2017.12.016.","journal-title":"Eur J Pharmacol"},{"key":"1282_CR100","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2023.2295431","author":"Z Fu","year":"2024","unstructured":"Fu Z, Geng X, Liu C, Shen W, Dong Z, Sun G, et al. Identification of common and specific fibrosis-related genes in three common chronic kidney diseases. Ren Fail. 2024. https:\/\/doi.org\/10.1080\/0886022x.2023.2295431.","journal-title":"Ren Fail"},{"key":"1282_CR101","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3892\/mmr.2017.8177","volume":"17","author":"C Cui","year":"2018","unstructured":"Cui C, Cui Y, Fu Y, Ma S, Zhang S. Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease. Mol Med Rep. 2018;17:2161\u20138. https:\/\/doi.org\/10.3892\/mmr.2017.8177.","journal-title":"Mol Med Rep"},{"key":"1282_CR102","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1172\/JCI81166","volume":"125","author":"J-H Baek","year":"2015","unstructured":"Baek J-H, Zeng R, Weinmann-Menke J, Valerius MT, Wada Y, Ajay AK, et al. IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J Clin Invest. 2015;125:3198\u2013214. https:\/\/doi.org\/10.1172\/JCI81166.","journal-title":"J Clin Invest"},{"key":"1282_CR103","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.20223311S1104c","volume":"33","author":"WY Ning","year":"2022","unstructured":"Ning WY, Zheng K, Wang G, Mei LX. IL-34 mediate the development of diabetic nephropathy by promoting macrophage infiltration: TH-PO200. J Am Soc Nephrol. 2022;33:104. https:\/\/doi.org\/10.1681\/ASN.20223311S1104c.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR104","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1681\/asn.2018090901","volume":"30","author":"Y Wada","year":"2019","unstructured":"Wada Y, Gonzalez-Sanchez HM, Weinmann-Menke J, Iwata Y, Ajay AK, Meineck M, et al. IL-34\u2013dependent intrarenal and systemic mechanisms promote lupus nephritis in MRL-faslpr mice. J Am Soc. 2019;30:244\u201359. https:\/\/doi.org\/10.1681\/asn.2018090901.","journal-title":"J Am Soc"},{"key":"1282_CR105","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1073\/pnas.88.16.7242","volume":"88","author":"PJ Lombroso","year":"1991","unstructured":"Lombroso PJ, Murdoch G, Lerner M. Molecular characterization of a protein-tyrosine-phosphatase enriched in striatum. Proc Natl Acad Sci USA. 1991;88:7242\u20136. https:\/\/doi.org\/10.1073\/pnas.88.16.7242.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1282_CR106","unstructured":"Tissue expression of PTPN5 - Summary - The Human Protein Atlas. 2026. https:\/\/www.proteinatlas.org\/ENSG00000110786-PTPN5\/tissue."},{"key":"1282_CR107","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1152\/ajprenal.00345.2017","volume":"314","author":"VL Halperin Kuhns","year":"2018","unstructured":"Halperin Kuhns VL, Pluznick JL. Novel differences in renal gene expression in a diet-induced obesity model. Am J Physiol Ren Physiol. 2018;314:F517\u201330. https:\/\/doi.org\/10.1152\/ajprenal.00345.2017.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1282_CR108","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1021\/acs.jafc.7b04743","volume":"66","author":"L Dong","year":"2018","unstructured":"Dong L, Li Y, Zhang D, Zhang H, Han J, Wang Z, et al. Dietary apostichopus japonicus alleviates diabetes symptoms and modulates genes expression in kidney tissues of db\/db mice. J Agric Food Chem. 2018;66:154\u201362. https:\/\/doi.org\/10.1021\/acs.jafc.7b04743.","journal-title":"J Agric Food Chem"},{"key":"1282_CR109","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/nyas.14002","volume":"1451","author":"GR Uhl","year":"2019","unstructured":"Uhl GR, Martinez MJ. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes. Ann NY Acad Sci. 2019;1451:112\u201329. https:\/\/doi.org\/10.1111\/nyas.14002.","journal-title":"Ann NY Acad Sci"},{"key":"1282_CR110","doi-asserted-by":"publisher","first-page":"12997","DOI":"10.18632\/oncotarget.4092","volume":"6","author":"Y-T Chen","year":"2015","unstructured":"Chen Y-T, Lin W-D, Liao W-L, Lin Y-J, Chang J-G, Tsai F-J. PTPRD silencing by DNA hypermethylation decreases insulin receptor signaling and leads to type 2 diabetes. Oncotarget Impact J. 2015;6:12997\u20133005. https:\/\/doi.org\/10.18632\/oncotarget.4092.","journal-title":"Oncotarget Impact J"},{"key":"1282_CR111","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/ijem.ijem_209_23","volume":"28","author":"R Saif-Ali","year":"2024","unstructured":"Saif-Ali R, Al-Hamodi Z, Salem SD, AL-Habori M, Al-Dubai SA, Ismail IS. Association of protein tyrosine phosphatase receptor type D and serine racemase genetic variants with type 2 diabetes in Malaysian Indians. Indian J Endocrinol Metab. 2024;28:55\u20139. https:\/\/doi.org\/10.4103\/ijem.ijem_209_23.","journal-title":"Indian J Endocrinol Metab"},{"key":"1282_CR112","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000513891","volume":"24","author":"Y Chen","year":"2021","unstructured":"Chen Y, Chen X-Y, Dong X-L, Wang Y-Z, Wang N, Zhu J-F, et al. Investigation of the association between 45 tag SNPs and type 2 diabetes mellitus in Han Chinese adults: a prospective cohort study. Public Health Genomics. 2021;24:123\u201330. https:\/\/doi.org\/10.1159\/000513891.","journal-title":"Public Health Genomics"},{"key":"1282_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.9994","volume":"21","author":"Y Kang","year":"2021","unstructured":"Kang Y, Huang H, Li H, Sun W, Zhang C. Functional genetic variants in the 3\u2019UTR of PTPRD associated with the risk of gestational diabetes mellitus. Exp Ther Med. 2021;21:1\u20137. https:\/\/doi.org\/10.3892\/etm.2021.9994.","journal-title":"Exp Ther Med"},{"key":"1282_CR114","doi-asserted-by":"publisher","first-page":"76101","DOI":"10.18632\/oncotarget.12599","volume":"7","author":"T Chen","year":"2016","unstructured":"Chen T, Xu J, Liu G, Liu H, Chen M, Qin Y, et al. Genetic variants in PTPRD and risk of gestational diabetes mellitus. Oncotarget. 2016;7:76101\u20137. https:\/\/doi.org\/10.18632\/oncotarget.12599.","journal-title":"Oncotarget."},{"key":"1282_CR115","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1038\/s41467-020-17076-w","volume":"11","author":"IM Hay","year":"2020","unstructured":"Hay IM, Fearnley GW, Rios P, K\u00f6hn M, Sharpe HJ, Deane JE. The receptor PTPRU is a redox sensitive pseudophosphatase. Nat Commun. 2020;11:3219. https:\/\/doi.org\/10.1038\/s41467-020-17076-w.","journal-title":"Nat Commun"},{"key":"1282_CR116","doi-asserted-by":"publisher","first-page":"15423","DOI":"10.1074\/jbc.M602607200","volume":"281","author":"H-X Yan","year":"2006","unstructured":"Yan H-X, Yang W, Zhang R, Chen L, Tang L, Zhai B, et al. Protein-tyrosine phosphatase PCP-2 inhibits \u03b2-catenin signaling and increases E-cadherin-dependent cell adhesion. J Biol Chem. 2006;281:15423\u201333. https:\/\/doi.org\/10.1074\/jbc.M602607200.","journal-title":"J Biol Chem"},{"key":"1282_CR117","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1002\/jcp.26174","volume":"233","author":"K Shao","year":"2018","unstructured":"Shao K, Shen L-S, Li H-H, Huang S, Zhang Y. Systematic-analysis of mRNA expression profiles in skeletal muscle of patients with type II diabetes: the glucocorticoid was central in pathogenesis. J Cell Physiol. 2018;233:4068\u201376. https:\/\/doi.org\/10.1002\/jcp.26174.","journal-title":"J Cell Physiol"},{"key":"1282_CR118","unstructured":"McKay R, Jain R, Dobie KW, Pandey SK, Bhanot S. Compositions and their uses directed to PTPRU. 2011. p. 118."},{"key":"1282_CR119","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.cmet.2006.03.006","volume":"3","author":"CY Cho","year":"2006","unstructured":"Cho CY, Koo S-H, Wang Y, Callaway S, Hedrick S, Mak PA, et al. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab. 2006;3:367\u201378. https:\/\/doi.org\/10.1016\/j.cmet.2006.03.006.","journal-title":"Cell Metab"},{"key":"1282_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073927","volume":"23","author":"J Kim","year":"2022","unstructured":"Kim J, Son J, Ahn D, Nam G, Zhao X, Park H, et al. Structure\u2013activity relationship of synthetic ginkgolic acid analogs for treating type 2 diabetes by PTPN9 inhibition. Int J Mol Sci. 2022;23:3927. https:\/\/doi.org\/10.3390\/ijms23073927.","journal-title":"Int J Mol Sci"},{"key":"1282_CR121","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/molecules26061612","volume":"26","author":"S-Y Yoon","year":"2021","unstructured":"Yoon S-Y, Yu JS, Hwang JY, So HM, Seo SO, Kim JK, et al. Phloridzin acts as an inhibitor of protein-tyrosine phosphatase MEG2 relevant to insulin resistance. Molecules. 2021;26:1612. https:\/\/doi.org\/10.3390\/molecules26061612.","journal-title":"Molecules"},{"key":"1282_CR122","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1158\/1541-7786.MCR-19-1142","volume":"18","author":"X-S Peng","year":"2020","unstructured":"Peng X-S, Yang J-P, Qiang Y-Y, Sun R, Cao Y, Zheng L-S, et al. PTPN3 inhibits the growth and metastasis of clear cell renal cell carcinoma via inhibition of PI3K\/AKT signaling. Mol Cancer Res. 2020;18:903\u201312. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-1142.","journal-title":"Mol Cancer Res"},{"key":"1282_CR123","doi-asserted-by":"publisher","first-page":"e99945","DOI":"10.15252\/embj.201899945","volume":"38","author":"B Yuan","year":"2019","unstructured":"Yuan B, Liu J, Cao J, Yu Y, Zhang H, Wang F, et al. PTPN3 acts as a tumor suppressor and boosts TGF-\u03b2 signaling independent of its phosphatase activity. EMBO J. 2019;38:e99945. https:\/\/doi.org\/10.15252\/embj.201899945.","journal-title":"EMBO J."},{"key":"1282_CR124","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2337\/db10-1270","volume":"60","author":"SC Elbein","year":"2011","unstructured":"Elbein SC, Kern PA, Rasouli N, Yao-Borengasser A, Sharma NK, Das SK. Global gene expression profiles of subcutaneous adipose and muscle from glucose-tolerant, insulin-sensitive, and insulin-resistant individuals matched for BMI. Diabetes. 2011;60:1019\u201329. https:\/\/doi.org\/10.2337\/db10-1270.","journal-title":"Diabetes"},{"key":"1282_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/br.2025.1931","volume":"22","author":"S-Y Chen","year":"2025","unstructured":"Chen S-Y, Tsai R-Y, Tseng T-J, Chen C-C. Elevated PTPN3 expression in type 2 diabetes mellitus: insights from genetic and experimental analyses. Biomed Rep. 2025;22:1\u20137. https:\/\/doi.org\/10.3892\/br.2025.1931.","journal-title":"Biomed Rep"},{"key":"1282_CR126","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1084\/jem.189.1.111","volume":"189","author":"J-F Cloutier","year":"1999","unstructured":"Cloutier J-F, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med. 1999;189:111\u201321. https:\/\/doi.org\/10.1084\/jem.189.1.111.","journal-title":"J Exp Med"},{"key":"1282_CR127","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ng1323","volume":"36","author":"N Bottini","year":"2004","unstructured":"Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36:337\u20138. https:\/\/doi.org\/10.1038\/ng1323.","journal-title":"Nat Genet"},{"key":"1282_CR128","doi-asserted-by":"publisher","first-page":"19767","DOI":"10.1073\/pnas.0706233104","volume":"104","author":"X Yu","year":"2007","unstructured":"Yu X, Sun J-P, He Y, Guo X, Liu S, Zhou B, et al. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci. 2007;104:19767\u201372. https:\/\/doi.org\/10.1073\/pnas.0706233104.","journal-title":"Proc Natl Acad Sci"},{"key":"1282_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70045","volume":"28","author":"J Shen","year":"2024","unstructured":"Shen J, Pan J, Yu G, Cai H, Xu H, Yan H, et al. Genetic interactions and pleiotropy in metabolic diseases: insights from a comprehensive GWAS analysis. J Cell Mol Med. 2024;28:e70045. https:\/\/doi.org\/10.1111\/jcmm.70045.","journal-title":"J Cell Mol Med"},{"key":"1282_CR130","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1507\/endocrj.EJ20-0239","volume":"68","author":"J Li","year":"2021","unstructured":"Li J, Wang Y, Zheng X, Sheng J, Guo H, Long W, et al. Quantitative evaluation of PTPN22 copy number variation by digital droplet PCR and association with type 2 diabetes risk. Endocr J. 2021;68:153\u201362. https:\/\/doi.org\/10.1507\/endocrj.EJ20-0239.","journal-title":"Endocr J"},{"key":"1282_CR131","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.kint.2024.04.017","volume":"106","author":"JX Zhou","year":"2024","unstructured":"Zhou JX, Li LX, Zhang H, Agborbesong E, Harris PC, Calvet JP, et al. DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age acceleration in autosomal dominant polycystic kidney disease. Kidney Int. 2024;106:258\u201372. https:\/\/doi.org\/10.1016\/j.kint.2024.04.017.","journal-title":"Kidney Int"},{"key":"1282_CR132","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/bj20021941","volume":"372","author":"JJ Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz JJ, T\u00e1rrega C, Blanco-Aparicio C, Pulido R. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1\/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochem J. 2003;372:193\u2013201. https:\/\/doi.org\/10.1042\/bj20021941.","journal-title":"Biochem J"},{"key":"1282_CR133","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.2337\/db08-0496","volume":"57","author":"RC Padmos","year":"2008","unstructured":"Padmos RC, Schloot NC, Beyan H, Ruwhof C, Staal FJT, de Ridder D, et al. Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes. 2008;57:2768\u201373. https:\/\/doi.org\/10.2337\/db08-0496.","journal-title":"Diabetes"},{"key":"1282_CR134","doi-asserted-by":"publisher","first-page":"e0129421","DOI":"10.1371\/journal.pone.0129421","volume":"10","author":"RL Balde\u00f3n","year":"2015","unstructured":"Balde\u00f3n RL, Weigelt K, De Wit H, Ozcan B, Van Oudenaren A, Semp\u00e9rtegui F, et al. Type 2 diabetes monocyte MicroRNA and mRNA expression: dyslipidemia associates with increased differentiation-related genes but not inflammatory activation. PLOS ONE. 2015;10:e0129421. https:\/\/doi.org\/10.1371\/journal.pone.0129421.","journal-title":"PLOS ONE."},{"key":"1282_CR135","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1006\/jaut.1996.0088","volume":"9","author":"AL Notkins","year":"1996","unstructured":"Notkins AL, Lu J, Li Q, VanderVegt FP, Wasserfall C, Maclaren NK, et al. IA-2 and IA-2\u03b2 are major autoantigens in IDDM and the precursors of the 40 kDa and 37 kDa tryptic fragments. J Autoimmun. 1996;9:677\u201382. https:\/\/doi.org\/10.1006\/jaut.1996.0088.","journal-title":"J Autoimmun"},{"key":"1282_CR136","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1006\/bbrc.1994.2549","volume":"204","author":"J Lu","year":"1994","unstructured":"Lu J, Notkins AL, Lan MS. Isolation, sequence and expression of a novel mouse-brain cDNA, mIA-2, and its relatedness to members of the protein tyrosine phosphatase family. Biochem Biophys Res Commun. 1994;204:930\u20136. https:\/\/doi.org\/10.1006\/bbrc.1994.2549.","journal-title":"Biochem Biophys Res Commun"},{"key":"1282_CR137","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1677\/JOE-07-0496","volume":"196","author":"J-C Henquin","year":"2008","unstructured":"Henquin J-C, Nenquin M, Szollosi A, Kubosaki A, Louis NA. Insulin secretion in islets from mice with a double knockout for the dense core vesicle proteins islet antigen-2 (IA-2) and IA-2\u03b2. J Endocrinol. 2008;196:573\u201381. https:\/\/doi.org\/10.1677\/JOE-07-0496.","journal-title":"J Endocrinol"},{"key":"1282_CR138","doi-asserted-by":"publisher","first-page":"1531723","DOI":"10.3389\/fendo.2025.1531723","volume":"16","author":"SS Stojilkovic","year":"2025","unstructured":"Stojilkovic SS, Sokanovic SJ, Constantin S. What is known and unknown about the role of neuroendocrine genes Ptprn and Ptprn2. Front Endocrinol. 2025;16:1531723. https:\/\/doi.org\/10.3389\/fendo.2025.1531723.","journal-title":"Front Endocrinol"},{"key":"1282_CR139","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1507\/endocrj.K09E-157","volume":"56","author":"S Torii","year":"2009","unstructured":"Torii S. Expression and function of IA-2 family proteins, unique neuroendocrine-specific protein-tyrosine phosphatases. Endocr J. 2009;56:639\u201348. https:\/\/doi.org\/10.1507\/endocrj.K09E-157.","journal-title":"Endocr J"},{"key":"1282_CR140","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1073\/pnas.0710931105","volume":"105","author":"H Mziaut","year":"2008","unstructured":"Mziaut H, Kersting S, Knoch K-P, Fan W-H, Trajkovski M, Erdmann K, et al. ICA512 signaling enhances pancreatic \u03b2-cell proliferation by regulating cyclins D through STATs. Proc Natl Acad Sci USA. 2008;105:674\u20139. https:\/\/doi.org\/10.1073\/pnas.0710931105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1282_CR141","doi-asserted-by":"publisher","first-page":"F382","DOI":"10.1152\/ajprenal.90543.2008","volume":"296","author":"SM Kim","year":"2009","unstructured":"Kim SM, Theilig F, Qin Y, Cai T, Mizel D, Faulhaber-Walter R, et al. Dense-core vesicle proteins IA-2 and IA-2\u03b2 affect renin synthesis and secretion through the \u03b2-adrenergic pathway. Am J Physiol Ren Physiol. 2009;296:F382-9. https:\/\/doi.org\/10.1152\/ajprenal.90543.2008.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1282_CR142","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4161\/epi.27161","volume":"9","author":"LJ Smyth","year":"2014","unstructured":"Smyth LJ, McKay GJ, Maxwell AP, McKnight AJ. DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics. 2014;9:366\u201376. https:\/\/doi.org\/10.4161\/epi.27161.","journal-title":"Epigenetics"},{"key":"1282_CR143","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00125-022-05735-0","volume":"65","author":"N Sandholm","year":"2022","unstructured":"Sandholm N, Cole JB, Nair V, Sheng X, Liu H, Ahlqvist E, et al. Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease. Diabetologia. 2022;65:1495\u2013509. https:\/\/doi.org\/10.1007\/s00125-022-05735-0.","journal-title":"Diabetologia"},{"key":"1282_CR144","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.bbrc.2009.09.117","volume":"390","author":"N Erdenebayar","year":"2009","unstructured":"Erdenebayar N, Maekawa Y, Nishida J, Kitamura A, Yasutomo K. Protein\u2013tyrosine phosphatase-kappa regulates CD4+ T cell development through ERK1\/2-mediated signaling. Biochem Biophys Res Commun. 2009;390:489\u201393. https:\/\/doi.org\/10.1016\/j.bbrc.2009.09.117.","journal-title":"Biochem Biophys Res Commun"},{"key":"1282_CR145","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.ygeno.2007.03.001","volume":"89","author":"H Kose","year":"2007","unstructured":"Kose H, Sakai T, Tsukumo S, Wei K, Yamada T, Yasutomo K, et al. Maturational arrest of thymocyte development is caused by a deletion in the receptor-like protein tyrosine phosphatase \u03ba gene in LEC rats. Genomics. 2007;89:673\u20137. https:\/\/doi.org\/10.1016\/j.ygeno.2007.03.001.","journal-title":"Genomics"},{"issue":"1","key":"1282_CR146","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00125-017-4440-y","volume":"61","author":"JRJ Inshaw","year":"2018","unstructured":"Inshaw JRJ, Walker NM, Wallace C, Bottolo L, Todd JA. The chromosome 6q22.33 region is associated with age at diagnosis of type 1 diabetes and disease risk in those diagnosed under 5\u00a0years of age. Diabetologia. 2018;61(1):147\u201357. https:\/\/doi.org\/10.1007\/s00125-017-4440-y.","journal-title":"Diabetologia"},{"key":"1282_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18296-4","volume":"12","author":"N Sandholm","year":"2022","unstructured":"Sandholm N, Rubio Garc\u00eda A, Pekalski ML, Inshaw JRJ, Cutler AJ, Todd JA. Thymocyte regulatory variant alters transcription factor binding and protects from type 1 diabetes in infants. Sci Rep. 2022;12:14137. https:\/\/doi.org\/10.1038\/s41598-022-18296-4.","journal-title":"Sci Rep"},{"key":"1282_CR148","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jpsychires.2017.09.021","volume":"96","author":"Y Chen","year":"2018","unstructured":"Chen Y, Xu C, Harirforoosh S, Luo X, Wang K-S. Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer\u2019s disease, cancer risk, and cholesterol. J Psychiatr Res. 2018;96:65\u201372. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.09.021.","journal-title":"J Psychiatr Res"},{"key":"1282_CR149","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1432-1327.1999.00004.x","volume":"259","author":"N Tanuma","year":"1999","unstructured":"Tanuma N, Nakamura K, Kikuchi K. Distinct promoters control transmembrane and cytosolic protein tyrosine phosphatase \u03b5 expression during macrophage differentiation. Eur J Biochem. 1999;259:46\u201354. https:\/\/doi.org\/10.1046\/j.1432-1327.1999.00004.x.","journal-title":"Eur J Biochem"},{"key":"1282_CR150","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1006\/excr.2002.5661","volume":"281","author":"J Kraut","year":"2002","unstructured":"Kraut J. Nuclear localization of non-receptor protein tyrosine phosphatase \u03b5 is regulated by its unique N-terminal domain. Exp Cell Res. 2002;281:182\u20139. https:\/\/doi.org\/10.1006\/excr.2002.5661.","journal-title":"Exp Cell Res"},{"key":"1282_CR151","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2108\/zsj.22.169","volume":"22","author":"Y Nakagawa","year":"2005","unstructured":"Nakagawa Y, Aoki N, Aoyama K, Shimizu H, Shimano H, Yamada N, et al. Receptor-type protein tyrosine phosphatase \u03f5 (PTP\u03f5M) is a negative regulator of insulin signaling in primary hepatocytes and liver. Zoolog Sci. 2005;22:169\u201375. https:\/\/doi.org\/10.2108\/zsj.22.169.","journal-title":"Zoolog Sci"},{"key":"1282_CR152","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1210\/en.2007-0908","volume":"149","author":"S Aga-Mizrachi","year":"2008","unstructured":"Aga-Mizrachi S, Brutman-Barazani T, Jacob AI, Bak A, Elson A, Sampson SR. Cytosolic protein tyrosine phosphatase-\u03b5 is a negative regulator of insulin signaling in skeletal muscle. Endocrinology. 2008;149:605\u201314. https:\/\/doi.org\/10.1210\/en.2007-0908.","journal-title":"Endocrinology"},{"key":"1282_CR153","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/cbin.70119","volume":"5","author":"S-C Li","year":"2024","unstructured":"Li S-C, Wang H, Shao Q-Y, Zhang J-H, Zeng M-Y, Bian W-K, et al. PTPRE aggravates vascular smooth muscle cells phenotypic transformation and vasomotor dysfunction in salt-sensitive hypertension. Cell Biol Int. 2024;5:50. https:\/\/doi.org\/10.1002\/cbin.70119.","journal-title":"Cell Biol Int."},{"key":"1282_CR154","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.5808\/gi.22029","volume":"20","author":"VSS Asmy","year":"2022","unstructured":"Asmy VSS, Natarajan J. Comparative co-expression analysis of RNA-Seq transcriptome revealing key genes, miRNA and transcription factor in distinct metabolic pathways in diabetic nerve, eye, and kidney disease. Genomics Inform. 2022;20:e26. https:\/\/doi.org\/10.5808\/gi.22029.","journal-title":"Genomics Inform"},{"key":"1282_CR155","doi-asserted-by":"publisher","first-page":"13468","DOI":"10.1038\/s41598-020-70540-x","volume":"10","author":"S Tang","year":"2020","unstructured":"Tang S, Wang X, Deng T, Ge H, Xiao X. Identification of C3 as a therapeutic target for diabetic nephropathy by bioinformatics analysis. Sci Rep. 2020;10:13468. https:\/\/doi.org\/10.1038\/s41598-020-70540-x.","journal-title":"Sci Rep"},{"key":"1282_CR156","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/376543","volume":"2011","author":"L Aoudjit","year":"2011","unstructured":"Aoudjit L, Jiang R, Lee TH, New LA, Jones N, Takano T. Podocyte protein, nephrin, is a substrate of protein tyrosine phosphatase 1B. J Signal Transduct. 2011;2011:376543. https:\/\/doi.org\/10.1155\/2011\/376543.","journal-title":"J Signal Transduct"},{"key":"1282_CR157","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1046\/j.1523-1755.2000.00070.x","volume":"57","author":"J Reiser","year":"2000","unstructured":"Reiser J, Pixley FJ, Hug A, Kriz W, Smoyer WE, Stanley ER, et al. Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases: rapid communication. Kidney Int. 2000;57:2035\u201342. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00070.x.","journal-title":"Kidney Int"},{"key":"1282_CR158","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1600-065X.2008.00747.x","volume":"228","author":"A Veillette","year":"2009","unstructured":"Veillette A, Rhee I, Souza CM, Davidson D. PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. Immunol Rev. 2009;228:312\u201324. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00747.x.","journal-title":"Immunol Rev"},{"key":"1282_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109554","volume":"69","author":"MA Held","year":"2020","unstructured":"Held MA, Greenfest-Allen E, Su S, Stoeckert CJ, Stokes MP, Wojchowski DM. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR\/JAK2 signaling. Cell Signal. 2020;69:109554. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109554.","journal-title":"Cell Signal"},{"key":"1282_CR160","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14670\/HH-18-767","volume":"40","author":"S Suo","year":"2024","unstructured":"Suo S, Chen S, Zhou L, Xu R, Li J, Li W. Mechanism of PTPN18 for regulating the migration and invasion of endometrial cancer cells via the MYC\/PI3K\/AKT pathway. Histol Histopathol. 2024;40:215\u201323. https:\/\/doi.org\/10.14670\/HH-18-767.","journal-title":"Histol Histopathol."},{"key":"1282_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-025-01803-8","volume":"17","author":"W Li","year":"2025","unstructured":"Li W, Zhong Q, Deng N, Zhou X, Wang H, Ouyang J, et al. Sphingolipid metabolism-related genes for the diagnosis of metabolic syndrome by integrated bioinformatics analysis and Mendelian randomization identification. Diabetol Metab Syndr. 2025;17:234. https:\/\/doi.org\/10.1186\/s13098-025-01803-8.","journal-title":"Diabetol Metab Syndr"},{"key":"1282_CR162","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/j.1460-2075.1992.tb05128.x","volume":"11","author":"M Streuli","year":"1992","unstructured":"Streuli M, Krueger NX, Ariniello PD, Tang M, Munro JM, Blattler WA, et al. Expression of the receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region. EMBO J. 1992;11:897\u2013907. https:\/\/doi.org\/10.1002\/j.1460-2075.1992.tb05128.x.","journal-title":"EMBO J"},{"key":"1282_CR163","doi-asserted-by":"publisher","first-page":"13811","DOI":"10.1016\/S0021-9258(19)49639-7","volume":"267","author":"N Hashimoto","year":"1992","unstructured":"Hashimoto N, Feener EP, Zhang WR, Goldstein BJ. Insulin receptor protein-tyrosine phosphatases. Leukocyte common antigen-related phosphatase rapidly deactivates the insulin receptor kinase by preferential dephosphorylation of the receptor regulatory domain. J Biol Chem. 1992;267:13811\u20134. https:\/\/doi.org\/10.1016\/S0021-9258(19)49639-7.","journal-title":"J Biol Chem"},{"key":"1282_CR164","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/JOE-12-0160","volume":"215","author":"S Gorgani-Firuzjaee","year":"2012","unstructured":"Gorgani-Firuzjaee S, Bakhtiyari S, Golestani A, Meshkani R. Leukocyte antigen-related inhibition attenuates palmitate-induced insulin resistance in muscle cells. J Endocrinol. 2012;215:71\u20137. https:\/\/doi.org\/10.1530\/JOE-12-0160.","journal-title":"J Endocrinol"},{"key":"1282_CR165","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1073\/pnas.071050398","volume":"98","author":"JM Zabolotny","year":"2001","unstructured":"Zabolotny JM, Kim Y-B, Peroni OD, Kim JK, Pani MA, Boss O, et al. Overexpression of the LAR (leukocyte antigen-related) protein-tyrosine phosphatase in muscle causes insulin resistance. Proc Natl Acad Sci U S A. 2001;98:5187\u201392. https:\/\/doi.org\/10.1073\/pnas.071050398.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1282_CR166","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1172\/JCI11798","volume":"95","author":"F Ahmad","year":"1995","unstructured":"Ahmad F, Considine RV, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. J Clin Invest. 1995;95:2806\u201312. https:\/\/doi.org\/10.1172\/JCI11798.","journal-title":"J Clin Invest."},{"key":"1282_CR167","doi-asserted-by":"publisher","first-page":"e0177192","DOI":"10.1371\/journal.pone.0177192","volume":"12","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Kim R, Park Y, Nguyen NG, Vestweber D, Dominguez MG, et al. Expression of receptor-type protein tyrosine phosphatase in developing and adult renal vasculature. PLoS ONE. 2017;12:e0177192. https:\/\/doi.org\/10.1371\/journal.pone.0177192.","journal-title":"PLoS ONE"},{"key":"1282_CR168","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1006\/excr.1999.4428","volume":"248","author":"C Bianchi","year":"1999","unstructured":"Bianchi C, Sellke FW, Vecchio RLD, Tonks NK, Neel BG. Receptor-type protein-tyrosine phosphatase m is expressed in specific vascular endothelial beds in vivo. Exp Cell Res. 1999;248:329\u201338. https:\/\/doi.org\/10.1006\/excr.1999.4428.","journal-title":"Exp Cell Res"},{"key":"1282_CR169","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/0955-0674(95)80106-5","volume":"7","author":"SM Brady-Kalnay","year":"1995","unstructured":"Brady-Kalnay SM, Tonks NK. Protein tyrosine phosphatases as adhesion receptors. Curr Opin Cell Biol. 1995;7:650\u20137. https:\/\/doi.org\/10.1016\/0955-0674(95)80106-5.","journal-title":"Curr Opin Cell Biol"},{"key":"1282_CR170","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1074\/jbc.M704195200","volume":"283","author":"Y Sakamoto","year":"2008","unstructured":"Sakamoto Y, Ogita H, Komura H, Takai Y. Involvement of nectin in inactivation of integrin \u03b1v\u03b23 after the establishment of cell-cell adhesion*. J Biol Chem. 2008;283:496\u2013505. https:\/\/doi.org\/10.1074\/jbc.M704195200.","journal-title":"J Biol Chem"},{"key":"1282_CR171","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1038\/sj.onc.1202794","volume":"18","author":"ES Pestana","year":"1999","unstructured":"Pestana ES, Tenev T, Gro\u00df S, Stoyanov B, Ogata M, B\u00f6hmer F-D. The transmembrane protein tyrosine phosphatase RPTP\u03c3 modulates signaling of the epidermal growth factor receptor in A431 cells. Oncogene. 1999;18:4069\u201379. https:\/\/doi.org\/10.1038\/sj.onc.1202794.","journal-title":"Oncogene"},{"key":"1282_CR172","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/mend.16.1.0756","volume":"16","author":"J Batt","year":"2002","unstructured":"Batt J, Asa S, Fladd C, Rotin D. Pituitary, pancreatic and gut neuroendocrine defects in protein tyrosine phosphatase- sigma-deficient mice. Mol Endocrinol. 2002;16:155\u201369. https:\/\/doi.org\/10.1210\/mend.16.1.0756.","journal-title":"Mol Endocrinol"},{"key":"1282_CR173","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1139\/y06-020","volume":"84","author":"MJ Chagnon","year":"2006","unstructured":"Chagnon MJ, Elchebly M, Uetani N, Dombrowski L, Cheng A, Mooney RA, et al. Altered glucose homeostasis in mice lacking the receptor protein tyrosine phosphatase sigma. Can J Physiol Pharmacol. 2006;84:755\u201363. https:\/\/doi.org\/10.1139\/y06-020.","journal-title":"Can J Physiol Pharmacol"},{"key":"1282_CR174","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1530\/EJE-07-0114","volume":"157","author":"E-C L\u00e5ngberg","year":"2007","unstructured":"L\u00e5ngberg E-C, Gu HF, Nordman S, Efendic S, \u00d6stenson C-G. Genetic variation in receptor protein tyrosine phosphatase \u03c3 is associated with type 2 diabetes in Swedish Caucasians. Eur J Endocrinol. 2007;157:459\u201364. https:\/\/doi.org\/10.1530\/EJE-07-0114.","journal-title":"Eur J Endocrinol"},{"key":"1282_CR175","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/HJH.0000000000003160","volume":"40","author":"O Berillo","year":"2022","unstructured":"Berillo O, Huo K-G, Richer C, Fraulob-Aquino JC, Briet M, Lipman ML, et al. Distinct transcriptomic profile of small arteries of hypertensive patients with chronic kidney disease identified miR-338-3p targeting GPX3 and PTPRS. J Hypertens. 2022;40:1394. https:\/\/doi.org\/10.1097\/HJH.0000000000003160.","journal-title":"J Hypertens"},{"key":"1282_CR176","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-021-00569-w","volume":"18","author":"H Liu","year":"2021","unstructured":"Liu H, Du T, Li C, Yang G. STAT3 phosphorylation in central leptin resistance. Nutr Metab. 2021;18:39. https:\/\/doi.org\/10.1186\/s12986-021-00569-w.","journal-title":"Nutr Metab"},{"key":"1282_CR177","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1073\/pnas.0611665104","volume":"104","author":"X Zhang","year":"2007","unstructured":"Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci USA. 2007;104:4060\u20134. https:\/\/doi.org\/10.1073\/pnas.0611665104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1282_CR178","doi-asserted-by":"publisher","first-page":"e100783","DOI":"10.1371\/journal.pone.0100783","volume":"9","author":"X Feng","year":"2014","unstructured":"Feng X, Scott A, Wang Y, Wang L, Zhao Y, Doerner S, et al. PTPRT regulates high-fat diet-induced obesity and insulin resistance. PLoS ONE. 2014;9:e100783. https:\/\/doi.org\/10.1371\/journal.pone.0100783.","journal-title":"PLoS ONE"},{"key":"1282_CR179","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s42003-022-03702-4","volume":"5","author":"D DiCorpo","year":"2022","unstructured":"DiCorpo D, Gaynor SM, Russell EM, Westerman KE, Raffield LM, Majarian TD, et al. Whole genome sequence association analysis of fasting glucose and fasting insulin levels in diverse cohorts from the NHLBI TOPMed program. Commun Biol. 2022;5:756. https:\/\/doi.org\/10.1038\/s42003-022-03702-4.","journal-title":"Commun Biol"},{"key":"1282_CR180","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10565-024-09865-6","volume":"40","author":"Y Liu","year":"2024","unstructured":"Liu Y, Qin Y, Zhang Y. circRNA-PTPN4 mediated regulation of FOXO3 and ZO-1 expression: implications for blood\u2013brain barrier integrity and cognitive function in uremic encephalopathy. Cell Biol Toxicol. 2024;40:22. https:\/\/doi.org\/10.1007\/s10565-024-09865-6.","journal-title":"Cell Biol Toxicol"},{"key":"1282_CR181","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2478\/s11658-013-0090-3","volume":"18","author":"J Zhou","year":"2013","unstructured":"Zhou J, Wan B, Shan J, Shi H, Li Y, Huo K. PTPN4 negatively regulates CrkI in human cell lines. Cell Mol Biol Lett BioMed Central. 2013;18:297\u2013314. https:\/\/doi.org\/10.2478\/s11658-013-0090-3.","journal-title":"Cell Mol Biol Lett BioMed Central"},{"key":"1282_CR182","doi-asserted-by":"publisher","first-page":"8312","DOI":"10.1007\/s11356-019-04212-3","volume":"26","author":"BH Chang","year":"2019","unstructured":"Chang BH, Cui B, Ullah H, Li S, Hao K, Tu X, et al. Role of PTP\/PTK trans activated insulin-like signalling pathway in regulation of grasshopper (Oedaleus asiaticus) development. Environ Sci Pollut Res. 2019;26:8312\u201324. https:\/\/doi.org\/10.1007\/s11356-019-04212-3.","journal-title":"Environ Sci Pollut Res"},{"key":"1282_CR183","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1158\/0008-5472.CAN-07-0513","volume":"67","author":"M Dromard","year":"2007","unstructured":"Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13\/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 2007;67:6806\u201313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0513.","journal-title":"Cancer Res"},{"key":"1282_CR184","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1677\/JOE-07-0262","volume":"197","author":"HJ Welters","year":"2008","unstructured":"Welters HJ, Oknianska A, Erdmann KS, Ryffel GU, Morgan NG. The protein tyrosine phosphatase-BL, modulates pancreatic \u03b2-cell proliferation by interaction with the Wnt signalling pathway. J Endocrinol. 2008;197:543\u201352. https:\/\/doi.org\/10.1677\/JOE-07-0262.","journal-title":"J Endocrinol"},{"key":"1282_CR185","doi-asserted-by":"publisher","first-page":"10919","DOI":"10.1074\/jbc.M707248200","volume":"283","author":"A Carlucci","year":"2008","unstructured":"Carlucci A, Gedressi C, Lignitto L, Nezi L, Villa-Moruzzi E, Avvedimento EV, et al. Protein-tyrosine phosphatase PTPD1 regulates focal adhesion kinase autophosphorylation and cell migration*. J Biol Chem. 2008;283:10919\u201329. https:\/\/doi.org\/10.1074\/jbc.M707248200.","journal-title":"J Biol Chem"},{"key":"1282_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-03041-4","volume":"25","author":"H Lian","year":"2024","unstructured":"Lian H, Xu K, Chang A, Wang Y, Ma S, Cheng L, et al. Loss of PTPN21 disrupted mitochondrial metabolic homeostasis and aggravated experimental pulmonary fibrosis. Respir Res. 2024;25:426. https:\/\/doi.org\/10.1186\/s12931-024-03041-4.","journal-title":"Respir Res"},{"key":"1282_CR187","doi-asserted-by":"publisher","first-page":"e103203","DOI":"10.1371\/journal.pone.0103203","volume":"9","author":"P Roda-Navarro","year":"2014","unstructured":"Roda-Navarro P, Bastiaens PI. Dynamic recruitment of protein tyrosine phosphatase PTPD1 to EGF stimulation sites potentiates EGFR activation. PLoS ONE. 2014;9:e103203. https:\/\/doi.org\/10.1371\/journal.pone.0103203.","journal-title":"PLoS ONE"},{"key":"1282_CR188","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1128\/MCB.24.11.4613-4626.2004","volume":"24","author":"L Cardone","year":"2004","unstructured":"Cardone L, Carlucci A, Affaitati A, Livigni A, de Cristofaro T, Garbi C, et al. Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol Cell Biol. 2004;24:4613\u201326. https:\/\/doi.org\/10.1128\/MCB.24.11.4613-4626.2004.","journal-title":"Mol Cell Biol"},{"key":"1282_CR189","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbrc.2007.10.022","volume":"364","author":"S Castiglioni","year":"2007","unstructured":"Castiglioni S, Maier JAM, Mariotti M. The tyrosine phosphatase HD-PTP: a novel player in endothelial migration. Biochem Biophys Res Commun. 2007;364:534\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2007.10.022.","journal-title":"Biochem Biophys Res Commun"},{"key":"1282_CR190","doi-asserted-by":"publisher","first-page":"jcs262032","DOI":"10.1242\/jcs.262032","volume":"137","author":"DF Schultz","year":"2024","unstructured":"Schultz DF, Davies BA, Payne JA, Martin CP, Minard AY, Childs BG, et al. Loss of HD-PTP function results in lipodystrophy, defective cellular signaling and altered lipid homeostasis. J Cell Sci. 2024;137:jcs262032. https:\/\/doi.org\/10.1242\/jcs.262032.","journal-title":"J Cell Sci."},{"key":"1282_CR191","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/emboj\/19.5.964","volume":"19","author":"X Zheng","year":"2000","unstructured":"Zheng X, Resnick RJ, Shalloway D. A phosphotyrosine displacement mechanism for activation of Src by PTP\u03b1. EMBO J. 2000;19:964\u201378. https:\/\/doi.org\/10.1093\/emboj\/19.5.964.","journal-title":"EMBO J"},{"key":"1282_CR192","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1002\/j.1460-2075.1993.tb06057.x","volume":"12","author":"J den Hertog","year":"1993","unstructured":"den Hertog J, Pals CE, Peppelenbosch MP, Tertoolen LG, de Laat SW, Kruijer W. Receptor protein tyrosine phosphatase alpha activates pp60c\u2010src and is involved in neuronal differentiation. EMBO J. 1993;12:3789\u201398. https:\/\/doi.org\/10.1002\/j.1460-2075.1993.tb06057.x.","journal-title":"EMBO J"},{"key":"1282_CR193","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bbrc.2003.10.011","volume":"311","author":"K Kapp","year":"2003","unstructured":"Kapp K, Metzinger E, Kellerer M, H\u00e4ring H-U, Lammers R. The protein tyrosine phosphatase \u03b1 modifies insulin secretion in INS-1E cells. Biochem Biophys Res Commun. 2003;311:361\u20134. https:\/\/doi.org\/10.1016\/j.bbrc.2003.10.011.","journal-title":"Biochem Biophys Res Commun"},{"key":"1282_CR194","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2013.28.3.415","volume":"28","author":"YJ Suh","year":"2013","unstructured":"Suh YJ, Kim S, Kim SH, Park J, Lim HA, Park HJ, et al. Combined genome-wide linkage and association analyses of fasting glucose level in healthy twins and families of Korea. J Korean Med Sci. 2013;28:415. https:\/\/doi.org\/10.3346\/jkms.2013.28.3.415.","journal-title":"J Korean Med Sci"},{"key":"1282_CR195","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-020-06898-z","volume":"21","author":"W Wang","year":"2020","unstructured":"Wang W, Zhang C, Liu H, Xu C, Duan H, Tian X, et al. Heritability and genome-wide association analyses of fasting plasma glucose in Chinese adult twins. BMC Genomics. 2020;21:491. https:\/\/doi.org\/10.1186\/s12864-020-06898-z.","journal-title":"BMC Genomics"},{"key":"1282_CR196","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2443.2008.01270.x","volume":"14","author":"H Sadakata","year":"2009","unstructured":"Sadakata H, Okazawa H, Sato T, Supriatna Y, Ohnishi H, Kusakari S, et al. SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis. Genes Cells. 2009;14:295\u2013308. https:\/\/doi.org\/10.1111\/j.1365-2443.2008.01270.x.","journal-title":"Genes Cells"},{"key":"1282_CR197","doi-asserted-by":"publisher","first-page":"34359","DOI":"10.1074\/jbc.M206541200","volume":"277","author":"T Takada","year":"2002","unstructured":"Takada T, Noguchi T, Inagaki K, Hosooka T, Fukunaga K, Yamao T, et al. Induction of apoptosis by stomach cancer-associated protein-tyrosine phosphatase-1*. J Biol Chem. 2002;277:34359\u201366. https:\/\/doi.org\/10.1074\/jbc.M206541200.","journal-title":"J Biol Chem"},{"key":"1282_CR198","doi-asserted-by":"publisher","first-page":"23929","DOI":"10.1074\/jbc.273.37.23929","volume":"273","author":"MB Wright","year":"1998","unstructured":"Wright MB, Hugo C, Seifert R, Disteche CM, Bowen-Pope DF. Proliferating and migrating mesangial cells responding to injury express a novel receptor protein-tyrosine phosphatase in experimental mesangial proliferative glomerulonephritis*. J Biol Chem. 1998;273:23929\u201337. https:\/\/doi.org\/10.1074\/jbc.273.37.23929.","journal-title":"J Biol Chem"},{"key":"1282_CR199","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0014-4827(03)00121-6","volume":"287","author":"RA Seifert","year":"2003","unstructured":"Seifert RA, Coats SA, Oganesian A, Wright MB, Dishmon M, Booth CJ, et al. PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein. Exp Cell Res. 2003;287:374\u201386. https:\/\/doi.org\/10.1016\/S0014-4827(03)00121-6.","journal-title":"Exp Cell Res"},{"key":"1282_CR200","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2174\/0929866529666220511141826","volume":"29","author":"W Zhang","year":"2022","unstructured":"Zhang W, Tang Z, Fan S, Yao D, Zhang Z, Guan C, et al. Protein tyrosine phosphatase receptor-type q: structure, activity, and implications in human disease. Protein Pept Lett. 2022;29:567\u201373. https:\/\/doi.org\/10.2174\/0929866529666220511141826.","journal-title":"Protein Pept Lett"},{"key":"1282_CR201","doi-asserted-by":"publisher","DOI":"10.3390\/genes15040489","volume":"15","author":"N Sakuma","year":"2024","unstructured":"Sakuma N, Nishio S, Goto S, Honkura Y, Oda K, Takeda H, et al. Detailed clinical features of PTPRQ-associated hearing loss identified in a large Japanese hearing loss cohort. Genes (Basel). 2024;15:489. https:\/\/doi.org\/10.3390\/genes15040489.","journal-title":"Genes (Basel)"},{"key":"1282_CR202","doi-asserted-by":"publisher","first-page":"9208","DOI":"10.1523\/JNEUROSCI.23-27-09208.2003","volume":"23","author":"RJ Goodyear","year":"2003","unstructured":"Goodyear RJ, Legan PK, Wright MB, Marcotti W, Oganesian A, Coats SA, et al. A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles. J Neurosci Soc Neuroscie. 2003;23:9208\u201319. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-27-09208.2003.","journal-title":"J Neurosci Soc Neuroscie"},{"key":"1282_CR203","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ajhg.2010.02.015","volume":"86","author":"M Schraders","year":"2010","unstructured":"Schraders M, Oostrik J, Huygen PLM, Strom TM, van Wijk E, Kunst HPM, et al. Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairment DFNB84 and associated with vestibular dysfunction. Am J Hum Genet. 2010;86:604\u201310. https:\/\/doi.org\/10.1016\/j.ajhg.2010.02.015.","journal-title":"Am J Hum Genet"},{"key":"1282_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-021-00871-9","volume":"14","author":"G Yang","year":"2021","unstructured":"Yang G, Yin Y, Tan Z, Liu J, Deng X, Yang Y. Whole-exome sequencing identified a novel heterozygous mutation of SALL1 and a new homozygous mutation of PTPRQ in a Chinese family with Townes-Brocks syndrome and hearing loss. BMC Med Genomics. 2021;14:24. https:\/\/doi.org\/10.1186\/s12920-021-00871-9.","journal-title":"BMC Med Genomics"},{"key":"1282_CR205","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/jhg.2015.88","volume":"60","author":"S Saka","year":"2015","unstructured":"Saka S, Hirawa N, Oka A, Yatsu K, Hirukawa T, Yamamoto R, et al. Genome-wide association study of IgA nephropathy using 23 465 microsatellite markers in a Japanese population. J Hum Genet. 2015;60:573\u201380. https:\/\/doi.org\/10.1038\/jhg.2015.88.","journal-title":"J Hum Genet"},{"key":"1282_CR206","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tips.2006.08.005","volume":"27","author":"AJ Barr","year":"2006","unstructured":"Barr AJ, Knapp S. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends Pharmacol Sci. 2006;27:525\u201330. https:\/\/doi.org\/10.1016\/j.tips.2006.08.005.","journal-title":"Trends Pharmacol Sci"},{"key":"1282_CR207","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2337\/diabetes.50.1.204","volume":"50","author":"A Bektas","year":"2001","unstructured":"Bektas A, Hughes JN, Warram JH, Krolewski AS, Doria A. Type 2 diabetes locus on 12q15: further mapping and mutation screening of two candidate genes. Diabetes. 2001;50:204\u20138. https:\/\/doi.org\/10.2337\/diabetes.50.1.204.","journal-title":"Diabetes"},{"key":"1282_CR208","doi-asserted-by":"publisher","first-page":"88","DOI":"10.62347\/VLDZ7581","volume":"13","author":"W Wang","year":"2024","unstructured":"Wang W. Identification of macrophage-related genes in bladder cancer patients using single-cell sequencing and construction of a prognostic model. Am J Clin Exp Immunol. 2024;13:88\u2013104. https:\/\/doi.org\/10.62347\/VLDZ7581.","journal-title":"Am J Clin Exp Immunol"},{"key":"1282_CR209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213947","author":"C Shen","year":"2023","unstructured":"Shen C, Chai W, Han J, Zhang Z, Liu X, Yang S, et al. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1213947.","journal-title":"Front Immunol"},{"key":"1282_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1198878","author":"H Chen","year":"2023","unstructured":"Chen H, Yang W, Li Y, Ma L, Ji Z. Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1198878.","journal-title":"Front Immunol"},{"key":"1282_CR211","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1042\/BJ20041932","volume":"389","author":"MT Fodero-Tavoletti","year":"2005","unstructured":"Fodero-Tavoletti MT, Hardy MP, Cornell B, Katsis F, Sadek CM, Mitchell CA, et al. Protein tyrosine phosphatase hPTPN20a is targeted to sites of actin polymerization. Biochem J. 2005;389:343\u201354. https:\/\/doi.org\/10.1042\/BJ20041932.","journal-title":"Biochem J"},{"key":"1282_CR212","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01910-w","volume":"26","author":"X Zuo","year":"2024","unstructured":"Zuo X, Zhao X, Zhang X, Li Q, Jiang X, Huang S, et al. PTPN20 promotes metastasis through activating NF-\u03baB signaling in triple-negative breast cancer. Breast Cancer Res. 2024;26:155. https:\/\/doi.org\/10.1186\/s13058-024-01910-w.","journal-title":"Breast Cancer Res"},{"key":"1282_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212692","author":"L Ma","year":"2023","unstructured":"Ma L, Liu Y, Wang Y, Yang J, Lu J, Feng H, et al. Identification of PTPN20 as an innate immunity-related gene in gastric cancer with Helicobacter pylori infection. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1212692.","journal-title":"Front Immunol"},{"key":"1282_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-021-00181-x","volume":"10","author":"H Yang","year":"2022","unstructured":"Yang H, Wang L, Shigley C, Yang W. Protein tyrosine phosphatases in skeletal development and diseases. Bone Res. 2022;10:10. https:\/\/doi.org\/10.1038\/s41413-021-00181-x.","journal-title":"Bone Res"},{"key":"1282_CR215","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5483\/BMBRep.2010.43.9.579","volume":"43","author":"N-K Lee","year":"2010","unstructured":"Lee N-K. An evolving integrative physiology: skeleton and energy metabolism. BMB Rep. 2010;43:579\u201383. https:\/\/doi.org\/10.5483\/BMBRep.2010.43.9.579.","journal-title":"BMB Rep"},{"key":"1282_CR216","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","volume":"130","author":"NK Lee","year":"2007","unstructured":"Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456\u201369. https:\/\/doi.org\/10.1016\/j.cell.2007.05.047.","journal-title":"Cell"},{"key":"1282_CR217","doi-asserted-by":"publisher","first-page":"H1796","DOI":"10.1152\/ajpheart.00781.2005","volume":"289","author":"OA Carretero","year":"2005","unstructured":"Carretero OA. Novel mechanism of action of ACE and its inhibitors. Am J Physiol Heart Circ Physiol. 2005;289:H1796-7. https:\/\/doi.org\/10.1152\/ajpheart.00781.2005.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1282_CR218","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","volume":"148","author":"R Kunz","year":"2008","unstructured":"Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148:30\u201348. https:\/\/doi.org\/10.7326\/0003-4819-148-1-200801010-00190.","journal-title":"Ann Intern Med"},{"key":"1282_CR219","first-page":"751","volume":"99","author":"K McGrath","year":"2019","unstructured":"McGrath K, Edi R. Diabetic kidney disease: diagnosis, treatment, and prevention. Am Fam Phys. 2019;99:751\u20139.","journal-title":"Am Fam Phys"},{"key":"1282_CR220","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"P Rossing","year":"2022","unstructured":"Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102:S1-127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","journal-title":"Kidney Int"},{"key":"1282_CR221","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"key":"1282_CR222","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233.","journal-title":"N Engl J Med"},{"key":"1282_CR223","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"key":"1282_CR224","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/biomedicines12030657","volume":"12","author":"M Rroji","year":"2024","unstructured":"Rroji M, Spasovski G. Transforming diabetes care: the molecular pathways through which GLP1-RAs impact the kidneys in diabetic kidney disease. Biomedicines. 2024;12:657. https:\/\/doi.org\/10.3390\/biomedicines12030657.","journal-title":"Biomedicines"},{"key":"1282_CR225","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf193","author":"T Sasaki","year":"2025","unstructured":"Sasaki T, Giang SM-L, Wu J, Yokoo T, Gallagher M, Bellomo R, et al. The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2025. https:\/\/doi.org\/10.1093\/ndt\/gfaf193.","journal-title":"Nephrol Dial Transplant"},{"key":"1282_CR226","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","volume":"37","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022;37:1014\u201323. https:\/\/doi.org\/10.1093\/ndt\/gfaa294.","journal-title":"Nephrol Dial Transplant"},{"key":"1282_CR227","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"1282_CR228","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13:15\u201328. https:\/\/doi.org\/10.1016\/S2213-8587(24)00271-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1282_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection. Am J Prev Cardiol. 2023;14:100502. https:\/\/doi.org\/10.1016\/j.ajpc.2023.100502.","journal-title":"Am J Prev Cardiol"},{"key":"1282_CR230","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med."},{"key":"1282_CR231","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"key":"1282_CR232","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1580645","author":"IS Alhomoud","year":"2025","unstructured":"Alhomoud IS, Albekery MA, Alqadi R, Alqumia A, Khan RA, Al Sahlawi M, et al. Finerenone in diabetic kidney disease: a new frontier for slowing disease progression. Front Med. 2025. https:\/\/doi.org\/10.3389\/fmed.2025.1580645.","journal-title":"Front Med"},{"key":"1282_CR233","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, Cho M, Pflueger A, Dunn SR, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22:1144\u201351. https:\/\/doi.org\/10.1681\/ASN.2010101049.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR234","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1681\/ASN.2014010012","volume":"26","author":"JF Navarro-Gonz\u00e1lez","year":"2015","unstructured":"Navarro-Gonz\u00e1lez JF, Mora-Fern\u00e1ndez C, de Fuentes M, Chahin J, M\u00e9ndez ML, Gallego E, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015;26:220\u20139. https:\/\/doi.org\/10.1681\/ASN.2014010012.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR235","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Brosius FC, Adler SG, Kretzler M, Mehta RL, Tumlin JA, et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol Dial Transplant. 2018;33:1950\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfx377.","journal-title":"Nephrol Dial Transplant"},{"key":"1282_CR236","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1384953","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Gong W, Wang Y, Hao C, Guan Y. Unraveling the nexus of NAD+ metabolism and diabetic kidney disease: insights from murine models and human data. Front Endocrinol. 2024;15:1384953. https:\/\/doi.org\/10.3389\/fendo.2024.1384953.","journal-title":"Front Endocrinol"},{"key":"1282_CR237","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10157-020-01917-5","volume":"24","author":"H Kanda","year":"2020","unstructured":"Kanda H, Yamawaki K. Bardoxolone methyl: drug development for diabetic kidney disease. Clin Exp Nephrol. 2020;24:857\u201364. https:\/\/doi.org\/10.1007\/s10157-020-01917-5.","journal-title":"Clin Exp Nephrol"},{"key":"1282_CR238","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.870049","volume":"10","author":"B Lin","year":"2022","unstructured":"Lin B, Ma Y-Y, Wang J-W. Nano-technological approaches for targeting kidney diseases with focus on diabetic nephropathy: recent progress, and future perspectives. Front Bioeng Biotechnol. 2022;10:870049. https:\/\/doi.org\/10.3389\/fbioe.2022.870049.","journal-title":"Front Bioeng Biotechnol"},{"key":"1282_CR239","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nat Med. 2025;31:45\u201359. https:\/\/doi.org\/10.1038\/s41591-024-03434-4.","journal-title":"Nat Med"},{"key":"1282_CR240","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11292-6","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Chen Y, Tao X, Wang Y, Tang F. An integrated approach for novel PTP1B inhibitor screening: combining machine learning models, molecular docking, molecular and dynamics simulations. Mol Divers. 2025. https:\/\/doi.org\/10.1007\/s11030-025-11292-6.","journal-title":"Mol Divers"},{"key":"1282_CR241","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11400-6","author":"Z Wang","year":"2025","unstructured":"Wang Z, Sun L, Ren A, Yang F, Chang Y. A transfer learning framework for PTP1B inhibitor activity prediction: differential modeling of natural and non-natural products with web platform implementation. Mol Divers. 2025. https:\/\/doi.org\/10.1007\/s11030-025-11400-6.","journal-title":"Mol Divers"},{"key":"1282_CR242","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11030-023-10710-x","volume":"28","author":"N Adhikari","year":"2024","unstructured":"Adhikari N, Ayyannan SR. Development and validation of machine learning models for the prediction of SH-2 containing protein tyrosine phosphatase 2 inhibitors. Mol Divers. 2024;28:1889\u2013905. https:\/\/doi.org\/10.1007\/s11030-023-10710-x.","journal-title":"Mol Divers"},{"key":"1282_CR243","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1681\/ASN.2012050445","volume":"24","author":"W Pichaiwong","year":"2013","unstructured":"Pichaiwong W, Hudkins KL, Wietecha T, Nguyen TQ, Tachaudomdach C, Li W, et al. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol. 2013;24:1088\u2013102. https:\/\/doi.org\/10.1681\/ASN.2012050445.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR244","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41574-025-01171-3","volume":"22","author":"V Martinez Leon","year":"2026","unstructured":"Martinez Leon V, Hilburg R, Susztak K. Mechanisms of diabetic kidney disease and established and emerging treatments. Nat Rev Endocrinol. 2026;22:21\u201335. https:\/\/doi.org\/10.1038\/s41574-025-01171-3.","journal-title":"Nat Rev Endocrinol"},{"key":"1282_CR245","doi-asserted-by":"publisher","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","volume":"40","author":"BL Neuen","year":"2025","unstructured":"Neuen BL, Yeung EK, Rangaswami J, Vaduganathan M. Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease. Nephrol Dial Transplant. 2025;40:i59-69. https:\/\/doi.org\/10.1093\/ndt\/gfae258.","journal-title":"Nephrol Dial Transplant"},{"key":"1282_CR246","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","volume":"40","author":"RZ Alicic","year":"2025","unstructured":"Alicic RZ, Neumiller JJ, Tuttle KR. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant. 2025;40:i3-17. https:\/\/doi.org\/10.1093\/ndt\/gfae212.","journal-title":"Nephrol Dial Transplant"},{"key":"1282_CR247","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/MNH.0000000000001197","volume":"35","author":"M Reaume","year":"2026","unstructured":"Reaume M, Tangri N. Remission in diabetic kidney disease: current evidence and future directions. Curr Opin Nephrol Hypertens. 2026;35:480. https:\/\/doi.org\/10.1097\/MNH.0000000000001197.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1282_CR248","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149:450\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067584.","journal-title":"Circulation"},{"key":"1282_CR249","unstructured":"AstraZeneca. A Phase III, Randomised, Double-blind, placebo-controlled, event-driven study to assess the efficacy, safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure. clinicaltrials.gov; 2025 Nov. Report No.: NCT06742723. https:\/\/clinicaltrials.gov\/study\/NCT06742723. Accessed 24 Nov 2025"},{"key":"1282_CR250","unstructured":"Boehringer Ingelheim. A Multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease. clinicaltrials.gov; 2025 Nov. Report No.: NCT06531824. https:\/\/clinicaltrials.gov\/study\/NCT06531824. Accessed 24 Nov 2025"},{"key":"1282_CR251","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/med.21871","volume":"42","author":"RM Elhassan","year":"2022","unstructured":"Elhassan RM, Hou X, Fang H. Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery. Med Res Rev. 2022;42:1064\u2013110. https:\/\/doi.org\/10.1002\/med.21871.","journal-title":"Med Res Rev"},{"key":"1282_CR252","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1021\/acs.biochem.3c00079","volume":"62","author":"W Asano","year":"2023","unstructured":"Asano W, Yamanaka K, Ohara Y, Uhara T, Doi S, Orita T, et al. Fragment-based discovery of novel VE-PTP inhibitors using orthogonal biophysical techniques. Biochemistry. 2023;62:2161\u20139. https:\/\/doi.org\/10.1021\/acs.biochem.3c00079.","journal-title":"Biochemistry"},{"key":"1282_CR253","unstructured":"Aerpio Therapeutics. Phase 2a Open label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with retinal vein occlusion. clinicaltrials.gov; 2018. Report No.: NCT02387788. https:\/\/clinicaltrials.gov\/study\/NCT02387788. Accessed 8 Oct 2025."},{"key":"1282_CR254","unstructured":"EyePoint Pharmaceuticals, Inc. Phase 2 Double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 (Razuprotafib)15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy. clinicaltrials.gov; 2023. Report No.: NCT03197870. https:\/\/clinicaltrials.gov\/study\/NCT03197870. Accessed 16 Sept 2025."},{"key":"1282_CR255","unstructured":"EyePoint Pharmaceuticals, Inc. Phase 2 Multi-center, double-masked, randomized, 28-day study to assess the efficacy, safety and tolerability of single or twice daily doses of AKB-9778 ophthalmic solution as an adjunct to latanoprost in patients with ocular hypertension (OHT) or open angle glaucoma (OAG). clinicaltrials.gov; 2023. Report No.: NCT04405245. https:\/\/clinicaltrials.gov\/study\/NCT04405245. Accessed 16 Sept 2025."},{"key":"1282_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114868","volume":"195","author":"IM Henderson","year":"2022","unstructured":"Henderson IM, Zeng F, Bhuiyan NH, Luo D, Martinez M, Smoake J, et al. Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development. Biochem Pharmacol. 2022;195:114868. https:\/\/doi.org\/10.1016\/j.bcp.2021.114868.","journal-title":"Biochem Pharmacol"},{"key":"1282_CR257","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1073\/pnas.1720446115","volume":"115","author":"GR Uhl","year":"2018","unstructured":"Uhl GR, Martinez MJ, Paik P, Sulima A, Bi G-H, Iyer MR, et al. Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist. Proc Natl Acad Sci. 2018;115:11597\u2013602. https:\/\/doi.org\/10.1073\/pnas.1720446115.","journal-title":"Proc Natl Acad Sci"},{"key":"1282_CR258","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1016\/j.bmc.2018.09.022","volume":"26","author":"B Ku","year":"2018","unstructured":"Ku B, Yun H-Y, Lee KW, Shin H-C, Lee S-R, Kim CH, et al. Identification of N-(5-(phenoxymethyl)-1,3,4-thiadiazol-2-yl)acetamide derivatives as novel protein tyrosine phosphatase epsilon inhibitors exhibiting anti-osteoclastic activity. Bioorg Med Chem. 2018;26:5204\u201311. https:\/\/doi.org\/10.1016\/j.bmc.2018.09.022.","journal-title":"Bioorg Med Chem"},{"key":"1282_CR259","unstructured":"Choi H-J. The change of bone markers after low dose alendronate in postmenopausal women. clinicaltrials.gov; 2014 Aug. Report No.: NCT00460057. https:\/\/clinicaltrials.gov\/study\/NCT00460057. Accessed 8 Oct 2025."},{"key":"1282_CR260","unstructured":"University of California, San Francisco. Alendronate prevents microarchitectural deterioration of trabecular bone in early postmenopausal. clinicaltrials.gov; 2013 July. Report No.: NCT00504166. https:\/\/clinicaltrials.gov\/study\/NCT00504166. Accessed 8 Oct 2025."},{"key":"1282_CR261","unstructured":"Mahidol University. Randomized trial comparing efficacy and safety of brand versus generic alendronate for osteoporosis treatment. clinicaltrials.gov; 2021 Sept. Report No.: NCT02371252. https:\/\/clinicaltrials.gov\/study\/NCT02371252. Accessed 8 Oct 2025."},{"key":"1282_CR262","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1038\/s41598-017-05931-8","volume":"7","author":"A Fujikawa","year":"2017","unstructured":"Fujikawa A, Sugawara H, Tanaka T, Matsumoto M, Kuboyama K, Suzuki R, et al. Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells. Sci Rep. 2017;7:5609. https:\/\/doi.org\/10.1038\/s41598-017-05931-8.","journal-title":"Sci Rep"},{"key":"1282_CR263","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04070-x","volume":"26","author":"K Takahashi","year":"2025","unstructured":"Takahashi K, Yu A, Otsuka T, Pasic L, Narui C, He L, et al. CD148 agonistic antibody alleviates renal injury induced by chronic angiotensin II infusion in mice. BMC Nephrol. 2025;26:165. https:\/\/doi.org\/10.1186\/s12882-025-04070-x.","journal-title":"BMC Nephrol"},{"key":"1282_CR264","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41467-019-11490-5","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Roos M, Himburg H, Termini CM, Quarmyne M, Li M, et al. PTP\u03c3 inhibitors promote hematopoietic stem cell regeneration. Nat Commun. 2019;10:3667. https:\/\/doi.org\/10.1038\/s41467-019-11490-5.","journal-title":"Nat Commun"},{"key":"1282_CR265","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2019.103391","volume":"99","author":"P Niknam","year":"2019","unstructured":"Niknam P, Raoufy MR, Fathollahi Y, Javan M. Modulating proteoglycan receptor PTP\u03c3 using intracellular sigma peptide improves remyelination and functional recovery in mice with demyelinated optic chiasm. Mol Cell Neurosci. 2019;99:103391. https:\/\/doi.org\/10.1016\/j.mcn.2019.103391.","journal-title":"Mol Cell Neurosci"},{"key":"1282_CR266","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neuropharm.2018.04.027","volume":"137","author":"R Fern\u00e1ndez-Calle","year":"2018","unstructured":"Fern\u00e1ndez-Calle R, Vicente-Rodr\u00edguez M, Pastor M, Gramage E, Di Geronimo B, Zapico JM, et al. Pharmacological inhibition of receptor protein tyrosine phosphatase \u03b2\/\u03b6 (PTPRZ1) modulates behavioral responses to ethanol. Neuropharmacology. 2018;137:86\u201395. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.04.027.","journal-title":"Neuropharmacology"},{"key":"1282_CR267","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/680348","volume":"2014","author":"M Ito","year":"2014","unstructured":"Ito M, Fukuda S, Sakata S, Morinaga H, Ohta T. Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice. J Diabetes Res. 2014;2014:680348. https:\/\/doi.org\/10.1155\/2014\/680348.","journal-title":"J Diabetes Res"},{"key":"1282_CR268","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2337\/dc17-2132","volume":"41","author":"A Digenio","year":"2018","unstructured":"Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, et al. Antisense inhibition of protein tyrosine phosphatase 1B with IONIS-PTP-1BRx improves insulin sensitivity and reduces weight in overweight patients with type 2 diabetes. Diabetes Care. 2018;41:807\u201314. https:\/\/doi.org\/10.2337\/dc17-2132.","journal-title":"Diabetes Care"},{"key":"1282_CR269","unstructured":"AbbVie. A Phase 1 Study with ABBV-CLS-484 alone and in combination in subjects with locally advanced or metastatic tumors. clinicaltrials.gov; 2025. Report No.: NCT04777994. https:\/\/clinicaltrials.gov\/study\/NCT04777994. Accessed 8 Oct 2025."},{"key":"1282_CR270","unstructured":"Kaneq Bioscience Limited. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of KQ-791 in subjects with type 2 diabetes. clinicaltrials.gov; 2019. Report No.: NCT02445911. https:\/\/clinicaltrials.gov\/study\/NCT02445911. Accessed 6 July 2026."},{"key":"1282_CR271","unstructured":"Gast M. A Phase I, Double-blind, randomized, placebo-controlled ascending iv multiple dose tolerance and pharmacokinetic study of trodusquemine (MSI-1436) in obese or overweight type 2 diabetic volunteers. clinicaltrials.gov; 2009. Report No.: NCT00806338. https:\/\/clinicaltrials.gov\/study\/NCT00806338. Accessed 8 Oct 2025."},{"key":"1282_CR272","unstructured":"Budman D. A Phase I Study of the safety and tolerability of single agent MSI-1436C in metastatic breast cancer patients. clinicaltrials.gov; 2018. Report No.: NCT02524951. https:\/\/clinicaltrials.gov\/study\/NCT02524951. Accessed 8 Oct 2025."},{"key":"1282_CR273","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240044","volume":"15","author":"GS Kumar","year":"2020","unstructured":"Kumar GS, Page R, Peti W. The mode of action of the protein tyrosine phosphatase 1B inhibitor Ertiprotafib. PLoS ONE. 2020;15:e0240044. https:\/\/doi.org\/10.1371\/journal.pone.0240044.","journal-title":"PLoS ONE"},{"key":"1282_CR274","unstructured":"Ionis Pharmaceuticals, Inc. A double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability, pharmacokinetics, and activity of ISIS 113715 in patients with type 2 diabetes mellitus who have not received prior therapy. clinicaltrials.gov; 2008. Report No.: NCT00330330. https:\/\/clinicaltrials.gov\/study\/NCT00330330. Accessed 8 Oct 2025."},{"key":"1282_CR275","unstructured":"Pharmaceuticals I. A Phase 2, Multi center, randomized, double blind, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, & activity of ISIS 113715 administered weekly in subjects with type 2 DM treated w\/ sulfonylurea. clinicaltrials.gov; 2009. Report No.: NCT00455598. https:\/\/clinicaltrials.gov\/study\/NCT00455598. Accessed 8 Oct 2025."},{"key":"1282_CR276","doi-asserted-by":"publisher","first-page":"12606","DOI":"10.1039\/d3sc04541b","volume":"14","author":"J Miao","year":"2023","unstructured":"Miao J, Dong J, Miao Y, Bai Y, Qu Z, Jassim BA, et al. Discovery of a selective TC-PTP degrader for cancer immunotherapy. Chem Sci. 2023;14:12606\u201314. https:\/\/doi.org\/10.1039\/d3sc04541b.","journal-title":"Chem Sci"},{"key":"1282_CR277","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117394","volume":"288","author":"X-Y Mu","year":"2025","unstructured":"Mu X-Y, Gao L-X, Zhang Z-X, Cao Z-T, Cao Q, Zhang C, et al. Development of coumarin and procaine linked hybrid molecules as a novel class of SHP1 fluorescent activators. Eur J Med Chem. 2025;288:117394. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117394.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"1282_CR278","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.4049\/jimmunol.0903562","volume":"184","author":"S Kundu","year":"2010","unstructured":"Kundu S, Fan K, Cao M, Lindner DJ, Zhao ZJ, Borden E, et al. Novel SHP-1 inhibitors TPI-1 and analogs with pre-clinical anti-tumor activities as tolerated oral agents. J Immunol. 1950;2010(184):6529\u201336. https:\/\/doi.org\/10.4049\/jimmunol.0903562.","journal-title":"J Immunol"},{"key":"1282_CR279","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202525126","volume":"62","author":"Z Qu","year":"2025","unstructured":"Qu Z, Meke FN, Zhang Z, Krabill AD, Muli CS, Jassim BA, et al. Discovery of a first-in-class covalent allosteric SHP1 inhibitor with immunotherapeutic activity. Angew Chem. 2025;62:e25126. https:\/\/doi.org\/10.1002\/ange.202525126.","journal-title":"Angew Chem"},{"key":"1282_CR280","unstructured":"M.D. Anderson Cancer Center. A Phase I, Open-Label, Dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of sodium stibogluconate in combination with interferon alpha-2b for patients with advanced malignancies. clinicaltrials.gov; 2018. Report No.: NCT00629200. https:\/\/clinicaltrials.gov\/study\/NCT00629200. Accessed 4 Feb 2026."},{"key":"1282_CR281","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110893","volume":"112","author":"F Zou","year":"2023","unstructured":"Zou F, Rao T, Chen W, Song T, Li T, Hu W, et al. DUSP2 affects bladder cancer prognosis by down-regulating MEK\/ERK and P38 MAPK signaling pathways through PTPN7. Cell Signal. 2023;112:110893. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110893.","journal-title":"Cell Signal"},{"key":"1282_CR282","doi-asserted-by":"publisher","DOI":"10.1039\/D5SC07398G","author":"ML Ware","year":"2026","unstructured":"Ware ML, Leace DM, Qu Z, Schaefer Q, Vaidya SD, Horvath ML, et al. Protein tyrosine phosphatase inactivation by electrophilic tyrosine modification. Chem Sci. 2026. https:\/\/doi.org\/10.1039\/D5SC07398G.","journal-title":"Chem Sci"},{"key":"1282_CR283","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","volume":"63","author":"M Wang","year":"2020","unstructured":"Wang M, Lu J, Wang M, Yang C-Y, Wang S. Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein. J Med Chem. 2020;63:7510\u201328. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00471.","journal-title":"J Med Chem"},{"key":"1282_CR284","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1124\/mol.106.025536","volume":"70","author":"L Chen","year":"2006","unstructured":"Chen L, Sung S-S, Yip MLR, Lawrence HR, Ren Y, Guida WC, et al. Discovery of a novel Shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol. 2006;70:562\u201370. https:\/\/doi.org\/10.1124\/mol.106.025536.","journal-title":"Mol Pharmacol"},{"key":"1282_CR285","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-020-00210-1","volume":"26","author":"J Jiang","year":"2020","unstructured":"Jiang J, Hu B, Chung C-S, Chen Y, Zhang Y, Tindal EW, et al. SHP2 inhibitor PHPS1 ameliorates acute kidney injury by Erk1\/2-STAT3 signaling in a combined murine hemorrhage followed by septic challenge model. Mol Med. 2020;26:89. https:\/\/doi.org\/10.1186\/s10020-020-00210-1.","journal-title":"Mol Med"},{"key":"1282_CR286","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0816-2","author":"J Chen","year":"2018","unstructured":"Chen J, Cao Z, Guan J. SHP2 inhibitor PHPS1 protects against atherosclerosis by inhibiting smooth muscle cell proliferation. BMC Cardiovasc Disord. 2018. https:\/\/doi.org\/10.1186\/s12872-018-0816-2.","journal-title":"BMC Cardiovasc Disord"},{"key":"1282_CR287","unstructured":"Genentech, Inc. A Phase Ib, Open-label study evaluating the safety, pharmacokinetics, and activity of GDC-1971 in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. clinicaltrials.gov; 2025. Report No.: NCT05487235. https:\/\/clinicaltrials.gov\/study\/NCT05487235. Accessed 2 Feb 2026."},{"key":"1282_CR288","unstructured":"Pfizer. A Phase 1, Open-Label, Multi-Center, Dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of anti-tumor activity of Pf-07284892 (Arry-558) as a single agent and in combination therapy in participants with advanced solid tumors. clinicaltrials.gov; 2024. Report No.: NCT04800822. https:\/\/clinicaltrials.gov\/study\/NCT04800822. Accessed 2 Feb 2026."},{"key":"1282_CR289","unstructured":"Dagogo-Jack I. A Phase IB\/II study of lorlatinib combinations in anaplastic lymphoma kinase-rearranged lung cancer. clinicaltrials.gov; 2021 Report No.: NCT04292119. https:\/\/clinicaltrials.gov\/study\/NCT04292119. Accessed 2 Feb 2026."},{"key":"1282_CR290","unstructured":"Allist Pharmaceuticals, Inc. An open-label, randomized, positive control, multicenter phase III clinical study. evaluating JAB-21822 combined with JAB-3312 compared tislelizumab combined with pemetrexed + carboplatin in the first line for treatment of advanced non-squamous non-small cell lung cancer with KRAS p.G12C mutation. clinicaltrials.gov; 2025. Report No.: NCT06416410. https:\/\/clinicaltrials.gov\/study\/NCT06416410. Accessed 2 Feb 2026."},{"key":"1282_CR291","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nchembio.916","volume":"8","author":"T Vang","year":"2012","unstructured":"Vang T, Liu WH, Delacroix L, Wu S, Vasile S, Dahl R, et al. LYP inhibits T cell activation when dissociated from CSK. Nat Chem Biol. 2012;8:437\u201346. https:\/\/doi.org\/10.1038\/nchembio.916.","journal-title":"Nat Chem Biol"},{"key":"1282_CR292","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.04.663030","author":"A Callahan","year":"2025","unstructured":"Callahan A, Puterbaugh RZ, Ro T, Zhang X, Su X, Salomon AR. Inclusion of the \u03b6-chain drives phosphotyrosine signalling in CD19-CAR T cells. Serv Biol. 2025. https:\/\/doi.org\/10.1101\/2025.07.04.663030.","journal-title":"Serv Biol."},{"key":"1282_CR293","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.1074\/jbc.RA118.007129","volume":"294","author":"K Li","year":"2019","unstructured":"Li K, Hou X, Li R, Bi W, Yang F, Chen X, et al. Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22. J Biol Chem. 2019;294:8653\u201363. https:\/\/doi.org\/10.1074\/jbc.RA118.007129.","journal-title":"J Biol Chem"},{"key":"1282_CR294","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1021\/jm400248c","volume":"56","author":"Y He","year":"2013","unstructured":"He Y, Liu S, Menon A, Stanford S, Oppong E, Gunawan AM, et al. A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. J Med Chem. 2013;56:4990\u20135008. https:\/\/doi.org\/10.1021\/jm400248c.","journal-title":"J Med Chem"},{"key":"1282_CR295","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115411","volume":"137","author":"SR Cummings","year":"2020","unstructured":"Cummings SR, Santora AC, Black DM, Russell RGG. History of alendronate. Bone. 2020;137:115411. https:\/\/doi.org\/10.1016\/j.bone.2020.115411.","journal-title":"Bone"},{"key":"1282_CR296","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/s0006-2952(97)00225-6","volume":"54","author":"E Opas","year":"1997","unstructured":"Opas E, Rutledge SJ, Golub E, Stern A, Rodan GA, Schmidt A. Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem Pharmacol. 1997;54:721\u20137. https:\/\/doi.org\/10.1016\/s0006-2952(97)00225-6.","journal-title":"Biochem Pharmacol"},{"key":"1282_CR297","unstructured":"Novartis Pharmaceuticals. A Phase 1, Open-label, Single-dose, Multi-center, parallel group study to evaluate the pharmacokinetics of TNO155 in participants with mild, moderate, or severe renal impairment compared to matched healthy control participants. clinicaltrials.gov; 2024. Report No.: NCT05541159. https:\/\/clinicaltrials.gov\/study\/NCT05541159. Accessed 16 Sept 2025."},{"key":"1282_CR298","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1517\/13543784.12.2.223","volume":"12","author":"Z-Y Zhang","year":"2003","unstructured":"Zhang Z-Y, Lee S-Y. PTP1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity. Expert Opin Investig Drugs. 2003;12:223\u201333. https:\/\/doi.org\/10.1517\/13543784.12.2.223.","journal-title":"Expert Opin Investig Drugs"},{"key":"1282_CR299","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.3390\/ijms23137027","volume":"23","author":"R Liu","year":"2022","unstructured":"Liu R, Mathieu C, Berthelet J, Zhang W, Dupret J-M, Rodrigues Lima F. Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives. Int J Mol Sci. 2022;23:7027. https:\/\/doi.org\/10.3390\/ijms23137027.","journal-title":"Int J Mol Sci"},{"key":"1282_CR300","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1210\/en.2008-0885","volume":"150","author":"MM Swarbrick","year":"2009","unstructured":"Swarbrick MM, Havel PJ, Levin AA, Bremer AA, Stanhope KL, Butler M, et al. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology. 2009;150:1670\u20139. https:\/\/doi.org\/10.1210\/en.2008-0885.","journal-title":"Endocrinology"},{"key":"1282_CR301","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41586-023-06575-7","volume":"622","author":"CK Baumgartner","year":"2023","unstructured":"Baumgartner CK, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel KM, Olander KE, Davis TGR, et al. The PTPN2\/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature. 2023;622:850\u201362. https:\/\/doi.org\/10.1038\/s41586-023-06575-7.","journal-title":"Nature"},{"key":"1282_CR302","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nm1397","volume":"12","author":"M-J Dubois","year":"2006","unstructured":"Dubois M-J, Bergeron S, Kim H-J, Dombrowski L, Perreault M, Fourn\u00e8s B, et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med. 2006;12:549\u201356. https:\/\/doi.org\/10.1038\/nm1397.","journal-title":"Nat Med"},{"key":"1282_CR303","doi-asserted-by":"publisher","DOI":"10.1186\/s12982-024-00247-1","volume":"21","author":"WJS Mota","year":"2024","unstructured":"Mota WJS, Guedes BN, Jain S, Cardoso JC, Severino P, Souto EB. Classical and innovative drugs for the treatment of Leishmania infections. Discov Public Health. 2024;21:122. https:\/\/doi.org\/10.1186\/s12982-024-00247-1.","journal-title":"Discov Public Health"},{"key":"1282_CR304","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.4049\/jimmunol.167.6.3391","volume":"167","author":"MK Pathak","year":"2001","unstructured":"Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines1. J Immunol. 2001;167:3391\u20137. https:\/\/doi.org\/10.4049\/jimmunol.167.6.3391.","journal-title":"J Immunol"},{"key":"1282_CR305","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1573618","author":"CK Bhusal","year":"2025","unstructured":"Bhusal CK, Sinha S, Kaur D, Sehgal R. Unravelling drug resistance in leishmaniasis: genomic adaptations and emerging therapies. Front Mol Biosci. 2025. https:\/\/doi.org\/10.3389\/fmolb.2025.1573618.","journal-title":"Front Mol Biosci"},{"key":"1282_CR306","doi-asserted-by":"publisher","DOI":"10.2337\/db19-45-OR","volume":"68","author":"VH Gonzalez","year":"2019","unstructured":"Gonzalez VH. 45-OR: The role of the angiopoietin-Tie2 pathway in microvascular complications of diabetes mellitus. Diabetes. 2019;68:45-OR. https:\/\/doi.org\/10.2337\/db19-45-OR.","journal-title":"Diabetes"},{"key":"1282_CR307","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1681\/ASN.V10102135","volume":"10","author":"T Takahashi","year":"1999","unstructured":"Takahashi T, Takahashi K, Mernaugh R, Drozdoff V, Sipe C, Schoecklmann H, et al. Endothelial localization of receptor tyrosine phosphatase, ECRTP\/DEP-1, in developing and mature renal vasculature. J Am Soc Nephrol. 1999;10:2135\u201345. https:\/\/doi.org\/10.1681\/ASN.V10102135.","journal-title":"J Am Soc Nephrol"},{"key":"1282_CR308","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1083\/jcb.200602080","volume":"174","author":"MG Lampugnani","year":"2006","unstructured":"Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol. 2006;174:593\u2013604. https:\/\/doi.org\/10.1083\/jcb.200602080.","journal-title":"J Cell Biol"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-026-01282-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-026-01282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:50:08Z","timestamp":1788342608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12929-026-01282-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":308,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1282"],"URL":"https:\/\/doi.org\/10.1186\/s12929-026-01282-7","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"89"}}